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Triple-negative breast cancer (TNBC) is am immunohistochemically-defined 
breast cancer subtype negative for ER, PR and HER2 expression, with dismal 
prognosis that lacks prognostic and predictive markers. Since all the aberrations that 
exist and ultimately contribute to the tumor phenotype converge, from a functional point 
of view, in the final status of the phosphorylation of the proteome in a given moment, we 
sought to interrogate the phosphoproteome with two aims: 1) establish a taxonomy of 
TNBC based on measurable markers that predict clinical course; 2) reduce the 
phosphoproteome that characterizes the bad- from good-prognosis cases to its 
targetable, driving kinases, in order to define rational therapeutic approaches in TNBC. 
Therefore we performed mass-spectrometry based quantitative phosphoproteomics 
from a training set of 34 frozen patient tumor samples paired by tumor size (T), nodal 
status (N), and grade (G). 13 patients relapsed in less than 3 years and 21 patients 
were relapse-free for more than 10 years follow up.  Moreover in our study we included 
ten triple-negative cell lines, 3 cell lines that killed recipient mice in less than 100 days 
and 7 indolent cell lines (no death in more than 400 days). In our study we were able to 
identify and quantify more than 17000 unique phosphopeptides (pPs) in the patient 
samples and cell lines. Differential analysis showed that 161 pPs were up-regulated in 
the relapsed vs non-relapsed group. Furthermore the hyperactivity of 11 kinases 
accounted for the pPs upregulated in the relapsed group. A mass-spectrometry-to-
immunohistochemistry translation step in 113 consecutive TNBC cases, spotted in 
TMAs, with 14 years follow up revealed that 6/11 kinases (PRKCE, KIT, PNKP, ERK, 
CDK6 and P70S6K) preserved independent prognostic value. The kinases split the 
validation set into two patterns: one (0/6 hyperactivated kinases; 29% of the patients) 
associated to 93.5 % cure rate. The other (≥1 hyperactivated kinase; 37 subpatterns) 
was associated to a 9.5-fold higher relapse risk. The 15 possible 2-drug combinations 
targeting these kinases were synergistic in vitro and in vivo. Our results elucidate novel 
phosposites/kinases implicated in TNBC and provide a ready to use, actionable targets-
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El cáncer de mama triple negativo (TNBC) es un subtipo de cáncer de mama 
definido inmunohistoquimicamente como negativo para la expresión de ER, PR y 
HER2, además carece de marcadores pronósticos y predictivos lo que hace que 
presente un mal pronóstico en general. Dado que todas las aberraciones genómicas 
presentes en el tumor contribuyen en el fenotipo tumoral y convergen, desde un punto 
de vista funcional, en el estado final de la fosforilación del proteoma en un momento 
dado, se intentó interrogar al fosfoproteoma con dos objetivos: 1) establecer una 
taxonomía de TNBC basado en marcadores medibles capaces de predecir el curso 
clínico; 2) simplificar el fosfoproteoma que distingue a pacientes con peor y mejor 
pronóstico llevado a cabo por las quinasas, con el fin de definir distintos enfoques 
terapéuticos en el TNBC. Por lo tanto hemos realizado un ánalisis fosfoproteómico 
cuantitativo, por espectrómetría de masas en un  grupo de 34 muestras de pacientes,  
agrupadas  por grado (G), tamaño del tumor (T) y estado de los ganglios (N). 13 de los 
pacientes recayeron en menos de 3 años y los otros 21 no presentaron recaida en más 
de 10 años de seguimiento.  Además en nuestro estudio se incluyeron diez líneas 
celurares triple negativas. La inyeccion de 3 de estas líneas celurares en ratones 
receptores fueron capaces de matarlos en menos de 100 días considerándose líneas 
agresivas, mientras que las  7 líneas celulares restantes no fueron capaces de matar a 
los ratones receptores en mas de 400 días y por ello se consideraron no agresivas. En 
nuestro estudio hemos podido identificar y cuantificar más de 17000 fosfopeptidos 
únicos, (pPs) presentes en las muestras de pacientes y líneas celulares. El análisis 
diferencial demostró que 161 de estos pPs idetificados estaban hiperregulados en el 
grupo de pacientes que recaían comparados con el grupo de pacientes sin recaída. 
Además, se identificaron 11 kinasas hiperactivas responsables de la hiperregulación de 
estos pPs, en el grupo de los pacientes que recaian. La validación de los resultados 
obtenidos mediante espectrometría de masas se llevo a cabo en una neuva seríe de 
113 muestras de casos de TNBC (con 14 años de seguimiento) que fueron incluidos  
en TMAs. Mediante técnicas inmunohistoquímicas observamos que 6 de las 11 kinasas 
identificadas (PRKCE, KIT, PNKP, ERK, CDK6 y P70S6K) conservaban un valor 
pronóstico independiente. Estas 6 kinasas son capaces de dividir el grupo de validación 
en dos patrones: uno asociado a la tasa de curación del 93,5% (0/6 kinasas 
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hiperactivadas; 29% de los pacientes) y el otro asociado a un mayor riesgo de recaida 
9.5-veces (≥1 kinasas hiperactivadas; 37 sub-patrones). El tratamiento con las 15 
posibles combinaciones de 2 fármacos dirigidos contra estas kinasas, fueron 
sinergisticas en tratamientos vitro y en vivo. Nuestros resultados identifican nuevos 
sitios de fosforilación y kinasas implicadas en el cáncer de mama triple negativo, 
proporcionando un nuevo sistema de clasificación basado en estos marcadores y que 
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TNBC  Triple-negative breast cancer 
T  Tumor size 
N  Nodal status 
G  Tumor grade  
pPs  Phosphopeptides 
ER  Oestrogen reseptor 
PR  Progesteron receptor 
HER2  Human epidermal growth factor receptor 2 
PARP            Poly - ADP ribose polymerase  
CK5/6           Cytokeratin 5/6  
EGFR  Epidermal growth factor receptor 
CL                 Claudin-low subtype  
BMI            Lowest body mass index  
HR  Hazard ratio 
CI  Confidence interval 
BLBC  Basal-like breast cancer 
PIK3CA Phosphatidylinositol 3-kinase, catalytic, alfa 
USH2A Ushers syndrome gene 
PTEN            Fosfatidilinositol-3,4,5-trisfosfato 3-fosfatasa 
RB1               Retinoblastoma 
COL6A3        Collagen type VI alpha 3 chain 
ATR               Ataxia telangiectasia and Rad3 related 
UBR5             Ubiquitin protein ligase E3 component n-recognin 5 
BRAF             B-Raf proto-oncogene, serine/threonine kinase 
ERBB2           Erb-b2 receptor tyrosine kinase 2 
ERBB3           Erb-b2 receptor tyrosine kinase 3 
BRCA1           Breast cancer susceptibility gene 1 
BRCA2           Breast cancer susceptibility gene 2 
RFS    Relapse-free survival 
OS    Overall survival 
DFS    Disease-free survival 
PFS    Progression-free survival 
PTMs    Posttranslational modifications 
RTKs    Receptor tyrosine kinases  
2D-PAGE   2-dimetional-polyacrile amide gel electrophoresis 
MS    Mass spectrometry 
ICAT    Isotope-coded affinity tag  
SILAC    Stable isotope labelling by amino acids in cell culture  
iTRAQ   Isobaric tags for relative and absolute quantification 
LC    Liquid chromatography  
Ser (S)   Serin 
Thr(T)             Threonin 
Tyr(Y)    Tyrosine 
DMEM   Dulbecco's Modified Eagle Medium  
EDTA              Ethylenediaminetetraacetic acid 
FBS    Fetal bovine serum 
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FFPE     Formalin-Fixed, Paraffin-Embedded 
HRP    Horseradish peroxidase 
HNU mice   Athymic Nude-Foxn1nu 
PBS    Phosphate buffered saline 
PEN    Penicillin  
RIPA    Radioimmunoprecipitation assay   
RNA    Ribonucleic acid 
RPMI    Roswell Park Memorial Institute medium 
STREP   Streptomycin 
SDS-PAGE   Sodium dodecyl sulfate polyacrylamide gel electrophoresis 
CDK6     Cyclin-dependent kinase 6 
PRKCE           Protein kinase C epsilon 
AKT                RAC-alpha serine/threonine-protein 
PNKP              Bifunctional polynucleotide phosphatase/kinase 
PIM1               Proto-oncogene Serine/threonine-protein kinase 
CLK1              Dual specificity protein kinase CLK1 
DAPK3            Death-associated protein kinase 3 
CHK1              Checkpoint kinase 1 
S6                   S6 ribosomal protein 
ERK1/2           Extracellular signal-regulated kinase 
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1. BREAST CANCER 
Even though being the subject of intensive investigation, breast cancer remains 
the most common cancer among woman, with greater than 1,300,000 cases and 
450,000 deaths each year worldwide1. In the last decades intensive research has led to 
better understanding of breast cancer origin, pathology and treatment options. These 
efforts have resulted in substantial improvement in the survival rate of breast cancer 
patients considering that the rate has increased up to 77% by the mid-nineties (Figure 
1). Unfortunately, the current long-term prognosis is not favourable and the death rates 
are still very high2. This highlights that more sensitive methods to detect breast cancer 
are needed and moreover that is extremely important to understand very early events of 
breast cancer biology in order to improve treatment modalities. 
 
Figure I1.  Overall survival rate of women diagnosed with breast cancer (adapted from Maxmen et al. 3) 
 
1.1. Risk factors for Breast Cancer 
 Although several risk factors for breast cancer have been documented, it is very 
difficult to identify specific risk factors for most women diagnosed4. Risk factors for this 
disease can be grouped in three categories: hereditary, hormonal and reproductive and 
environmental factors5.  
 A familiar history of breast cancer increases the risk by a factor of two or three. In 
particular the BRCA1 gene has been implicated in the pathogenesis of hereditary breast 
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cancer whereby women with mutations in either BRCA1 or BRCA2 have a 60% to 85% 
lifetime risk for developing breast cancer6. Mutations in p53 account for 1% of early 
onset breast cancer7, and thus account for a small portion of the total breast cancer 
burden. Beck in 1994, Guinee at al.  were the first to suggest a link between breast 
cancer and hormonal and reproductive factors. These authors showed the association 
between the incidence of breast cancer and the age of menarche, first pregnancy and 
menopause. In particular, those woman who become pregnant after the age of 35, have 
a two to threefold higher risk of breast cancer than those women whose pregnancy 
occurred before age 258. Moreover environmental factors including smoking, dietary 
factors and different chemicals have also been found to influence the risk of breast 
cancer9. 
 
1.2. Classification of Breast Cancer 
Breast cancer is considered to be a highly heterogeneous disease. Indeed, 
different types of this cancer exhibit different histopathological and biological features, 
clinical outcome and response to systemic interventions. Thus, due to this high degree 
of heterogeneity, this disease cannot be viewed as a single clinico-pathological entity, 
but rather must be dissected into a number of more homogeneous groups. For 
classification of any disease, a suitable one has to be easily applicable, widely 
reproducible and most importantly clinically useful. When it comes to breast cancer, 
unfortunately, despite all the efforts in past and recent years, the ‘perfect’ classification 
is still lacking.  
1.2.1. Histological types of breast cancer   
The histopathological classification of breast tumors is based on the diversity of its 
morphological features. Broadly, breast cancer can be categorized into in situ 
carcinoma (if the tumor is limited to the epithelial component) and invasive (infiltrating) 
carcinoma (if the tumor has invaded the stroma). Moreover, histological appearance 
depends on the organ compartment in which the tumor has originated, such as inner 
lining epithelium of the ducts (ductal carcinoma) or the lobules that supply the ducts with 
milk (lobular carcinoma) 10.  
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Figure I2. Ductal carcinoma of the breast (adapted from http://ungbuouvietnam.com/ung-thu-bieu-
mo-tuyen-vu-xam-lan/) 
 
Adenocarcinomas are found in more than 95% of the patients11 and invasive ductal 
carcinoma (IDC) is the most common form of invasive breast cancer. It accounts for 
55% of breast cancer incidence upon diagnosis12.. While this classification scheme has 
been a valuable tool for several decades, it relies solely on histology without utilizing 
newer molecular markers that have a proven prognostic significance. 
1.2.2. Molecular types of breast cancer 
In the last decade, many efforts have been made to substitute the histopathological 
classification with molecular parameters that can both provide better prediction of tumor 
behaviour and improve therapeutic strategies. In line with this, Perou and colleagues 
were able to identify molecular defined classes of breast cancer using hierarchical 
clustering analysis and similarities in gene expression profiles13 . The subtypes of breast 
cancers identified by their gene signature are:  
Luminal A - accounts for 50% of invasive breast cancers. It is oestrogen and 
progesterone (ER/PR) positive or HER2 negative. It has a good prognosis and is 
typically of low pathological grade and low proliferation rates14. 
Luminal B - comprises 20% of invasive breast cancers. The oestrogen/progesterone 
expression (ER/PR) is positive, while human epidermal growth factor receptor 2 (HER2) 
expression is variable (positive or negative). The proliferation index expressed by Ki-67 
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staining and histological grades are higher than luminal A. The response to endocrine 
therapy and chemotherapy is variable, and its prognosis is poorer than luminal A14.  
Her2 overexpression - accounts for 15% of all invasive breast cancers. The ER/PR is 
usually negative, while HER2 is strong positive. It’s characterized by high Ki-67 
expression and common mutation of TP53. This group of breast cancer implies poor 
prognosis and shows the highest sensitivity to trastuzumab (herceptin) therapy. 
Basal like – this class is so named due to its pattern of expression that is similar to 
basal epithelial cells and normal myoepithelial cells of mammary tissue. Typically is 
cytokeratin 5/6 (CK5/6) and/or EGFR positive, ER/ PR negative, and HER2 negative 
(triple negative) with a high expression of Ki-67 and common TP53 mutations. In terms 
of treatment options, this type of breast cancer do not respond to endocrine therapy or 
trastuzumab but shows some sensitivity to platinum-based chemotherapy and poly - 
ADP ribose polymerase (PARP) inhibitors. In general has poor prognosis.  
 
Figure I3. Molecular types of breast cancer (adapted from http://www.pathophys.org/breast- 
cancer/) 
 
It should be noted that this classification based on molecular and 
immunohistochemical parameters do not overlap completely, since some basal-like 
breast cancers (according to the molecular classification) will not show the expected 
triple-negative (ER, PR and HER2 negative) immunophenotype and vice versa, not all 
triple-negative breast cancer will be classified as basal-like by gene expression profiling.  
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In 2007, a new intrinsic subtype was described, the claudin-low subtype (CL), through 
the combined analysis of murine mammary carcinoma models and human breast 
cancers15. This subtype represented 6% of the breast cancer samples analyzed. CL 
tumors lack tight junction proteins including claudin 3 and E-cadherin15 and are 
characterized by low to absent expression of luminal differentiation markers, high 
enrichment for epithelial-to-mesenchymal transition markers, immune response genes 
and cancer stem cell-like features.  
 
 
Figure I4. Cluster diagram of intrinsic subtypes highlighting the claudin-low subtype. Abbreviations: 
EMT, epithelial–mesenchymal transition; HER-2, human epidermal growth factor receptor; TN, triple 
negative. (Adapted from Perou et al16) 
 
Clinically, the majority of claudin-low tumors are poor prognosis oestrogen receptor 
(ER)-negative, progesterone receptor (PR)-negative, and epidermal growth factor 
receptor 2 (HER2)-negative (triple negative) invasive ductal carcinomas with a high 
frequency of metaplastic and medullary differentiation. They also have a response rate 
to standard preoperative chemotherapy that is intermediate between that of basal-like 
and luminal tumors15,17,18. Today, with less than 90 samples characterized, the CL 
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2. TRIPLE-NEGATIVE BREAST CANCER 
Triple negative breast cancer (TNBC) has recently been recognized as an 
important subgroup of breast cancer with a distinct outcome and therapeutic approach 
when compared to other subgroups of breast cancer.  This subtype is characterized by 
the absence of oestrogen and progesterone receptor expression and no overexpression 
of human epidermal growth factor receptor 2 (HER2). In different series and patient 
populations TNBC may range between 6–28% of breast cancers19–21, but even higher 
incidence rates are reported for some ethnical groups such as African Americans and 
for younger patients22. Although it accounts for a relatively small minority of breast 
cancer cases (10–17 %)23, TNBC is responsible for a disproportionate number of breast 
cancer deaths. Moreover, there have been fewer advances in the treatment of TNBC 
than of other subtypes. For these reasons, new research initiatives for TNBC are 
critical24. 
2.1. Risk factors for Triple Negative Breast Cancer 
Two studies have shown that reproductive factors — specifically, pregnancy and 
multiple childbirth, obesity and lack of physical activity increase the risk for TNBC. In the 
first study, the researchers found that obese women had a 35% higher risk for TNBC 
than women with a lowest body mass index (BMI); in the second study, women who had 
never given birth had a 40% lower risk for the disease than those who had experienced 
a full-term pregnancy. Surprisingly, the number of births affected the risk for TNBC; 
women who had given birth to 3 or more children were at higher risk than women who 
had given birth to 1 child (hazard ratio [HR], 1.46; 95% confidence interval [CI], 0.82 to 
2.63)25. 
2.2. TNBC versus BLBC 
 Triple negative breast cancers is described as a type of breast cancer that lacks 
expression of oestrogen receptor (ER), progesterone receptor (PR) and HER2. 
Moreover they are characterized by its similarity to basal-like cancers including the fact 
that they more frequently affect younger patients (<50 years)19,26,27, are more prevalent 
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in African-American women28, often present as interval cancers and are significantly 
more aggressive than tumors of other molecular subtypes19,29. This aggressiveness is 
best exemplified by the fact that the pick of recurrence is between the first and the third 
year and the majority of deaths occur in first 5 years following treatment21,30. Patients 
with triple negative cancers21, similar to those with basal-like cancers have significantly 
shorter survival following the first metastatic event when compared with those with non-
triple-negative/non-basal like controls. 
 
 
Figure I5. Survival after a Diagnosis of Breast Cancer. Panel A shows the survival rate in a series of 
3744 patients according to immunohistochemical subtype. Panel B shows the hazard rates for distant 
recurrence of triple-negative breast cancer and non-triple negative breast cancer (adapted from Foulkes 
et al.31) 
 
Several studies have shown that majority of TNBC cancers are of basal 
phenotype20,32,33 and vice versa that majority of tumors expressing ‘basal’ markers are 
triple-negative20,34–36. However, not all basal-like cancers determined by gene 
expression profiling lack ER, PR and HER234,36–39 and conversely not all triple-negative 
cancers show a basal-like phenotype by expression array analysis. For example, 
Bertucci et al36 showed that only 71% of triple-negative cancers were of basal-like gene 
expression profile. On the other hand only 77% of molecular basal-like tumors were 
triple-negative40,41. Further, there is a significant number of triple-negative cancers that 
do not express basal markers and are classified as other breast cancer subgroups, 
such as normal breast-like41–44 or claudin-low15,45. These findings suggest that when 
analyzed by gene expression profiling TNBC do not form homogeneous group. In 
contrast, the basal-like subtype does form a homogeneous group of tumors with a 
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similar gene expression profiling related to prognosis and therapy response36,46. Thus, 
the overall poor prognosis of TNBC may be a result of this basal-like subgroup, and 
triple negativity may be seen more as a symptom than as a separate entity of breast 
cancer. In line with this, triple-negative phenotype may not be an ideal surrogate marker 
for basal-like breast cancer15,36.  
 
 
Figure I6.Overlap between triple-negative and basal-like breast cancer (adopted from 
http://www.medscape.org/viewarticle/587289) 
 
2.3. Molecular characteristics of triple-negative breast cancer 
 Genomic profiles of TNBC have recently been defined using whole exome 
sequencing which revealed that TNBC patients harbor germ line mutations in tumor 
relevant genes47, such as PALB2, but also high numbers of somatic mutations48,49. 
These studies together with others50,51, have discovered that one of the most frequently 
mutated genes is p53 with 62% of basal TNBC (determined by PAM5041 analysis on 
RNASeq expression profiles) and 43% of non-basal TNBC cases harboring a validated 
somatic mutation. The same study also found frequent mutations in PIK3CA at 10.2%, 
USH2A (Ushers syndrome gene, implicated in actin cytoskeletal functions) at 9.2%, 
PTEN and RB1 at 7.7% (5/65) and a further 8 genes (including ATR, UBR5 (EDD1), 
COL6A3) at 6.2% (4/65) of cases in the cohort. Approximately 20% of cases contained 
examples of potentially “clinically actionable” somatic aberrations, including BRAF 
V600E, high-level EGFR amplifications and ERBB2/ERBB3 mutations. Moreover, both 
TNBC and basal-like breast cancer show considerable overlap with BRCA1-mutated 
tumours52. BRCA1 is an important tumor suppressor gene that plays a vital role in DNA 
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repair22. Thus the lack of BRCA1 results in DNA repair by more error-prone 
mechanisms, resulting in genomic instability. Clustering analysis of microarray RNA 
expression data have shown that familial-BRCA1 mutant tumors strongly segregate with 
triple-negative sporadic tumors, suggesting similar carcinogenic pathways or cause of 
these two subtypes53. BRCA1 deficiency (as assessed by mutation, methylation, and 
BRCA1-like comparative genomic hybridization (CGH) profile analysis) is observed in ∼50% of patients with TNBC.  
 
Figure I7. Shared features of triple-negative, basal-like and BRCA1-associated breast cancers (adopted 
from Carey et al.54. 
 
BRCA1-associated cancers show a further similarity with triple-negative cancer, in that 
p53 is commonly mutated, although the spectrum on mutations is distinct from that 
occurring in triple-negative breast cancer.  
There is increasing evidence that the DNA-repair defects characteristic of BRCA-related 
cancer, especially defective homologous recombination, confer sensitivity to certain 
systemic agents55,56, which could be relevant to the treatment of triple-negative breast 
cancer. In vitro data have shown that inhibition of ADP-ribose-polymerase (PARP)-1 
leads to highly selective apoptosis of BRCA1 null cells57. At this regard, in December 
2014, the FDA approved olaparib (PARP inhibitor) as monotherapy for the treatment of 
patients with germline BRCA-mutated advanced ovarian cancer who have been treated 
with three or more prior lines of chemotherapy. In addition there are active phase III 
studies for olaparib and other PARP inhibitors in metastatic breast cancer for patients 
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with BRCA1/2 mutations. Nevertheless, it remains unclear whether a positive test for 
BRCA1/2 mutations can lead to a reliable determination about which patients will benefit 
from PARP inhibitor therapy.  
2.4. Clinical features of TNBC 
TNBC is characterized as an aggressive disease with poor clinical outcomes, including 
short durations of relapse-free survival (RFS) and overall survival (OS)53. Data show 
that a high proportion of patients with TNBC (~34%) experience distant recurrence, with 
a mean of 2.6 years to distant recurrence, whereas in other breast cancer subtypes 
distant recurrence rate is of 20%, with a mean of 5 years to distant recurency21. The 5-
year OS rate is also inferior for patients with TNBC compared with the rate of 5-year OS 
observed for other types of breast cancer. In TNBC, the risk of recurrence peaks within 
the first 3 years after diagnosis and then decreases21,58. Patients with TNBC are most 
likely to experience recurrence in the visceral organs. In line with this, study done by 
Liedtke and colleagues found that 74% of patients with TNBC developed recurrences in 
visceral organs; but only 13% of patients developed recurrences in the soft tissue and in 
bone58. 
 
Figure I8. Sites of First Distant Recurrence in Cases of Metastatic Triple-Negative Breast Cancer as 
Compared with Non–Triple-Negative Breast Cancer. The percentages shown are approximate 
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Furthermore, TNBC tend to be grade III and large (>2.0 cm) at diagnosis21. They 
have been associated with a higher rate of lymph node positivity than other breast 
cancer subtypes, but there is not apparent correlation between tumor size and nodal 
status. 
2.5. Treatment of TNBC 
TNBC is a complex disease because no dominant oncogenic factor has been 
identified as a driver of tumor cell proliferation. It is well established that TNBC is an 
aggressive group of breast cancer subtypes despite having a good initial response to 
chemotherapy. Moreover, it was found that patients with residual TNBC disease post 
neo-adjuvant chemotherapy have a worse prognosis than those with non-TNBC29. 
Importantly, there is no preferred standard chemotherapy for these patients and 
typically tumour size, lymph node status, grade and overall performance status will 
determine the regimens used. For women presenting with triple negative breast cancer 
(TNBC), it is established that in the absence of ER, PR and HER-2, endocrine therapies 
such as tamoxifen and aromatase inhibitors and as well as HER-2 directed therapies 
such as trastazumab and lapatinib are not efficacious. However, triple negative breast 
cancers seem to be particularly chemo-sensitive to anthracyclines and taxanes that are 
part of the standard therapy used for high-risk patients, for example those patients with 
node positive disease. Unfortunately, in spite of this, there is an overall poorer 
survival59. 
 Neoadjuvant chemotherapy can be used to improve subsequent surgical 
intervention and/or for testing novel therapies or combinations. Historically, TNBC 
patients responded well in the neoadjuvant setting, with rates of pathological complete 
response (pCR) commonly higher than those observed for other breast tumour types60. 
Published trials have also shown that TNBC patients benefit from adjuvant 
chemotherapy. In the prospective BCIRG 001 study, a chemotherapy regimen 
comprising combination of docetaxel/doxorubicin/cyclophosphamide (TAC) was 
compared with fluorouracil/doxorubicin-cyclophosphamide (FAC) in patients with lymph 
node–positive breast cancer61. This study showed that TNBC patients had a better 
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response to the TAC regimen than to the FAC regimen; 3-year DFS rates were 73.5% 
versus 60% (HR, 0.50; 95% CI, 0.29-1.00; P = .051). Thus, the TAC regimen may be 
beneficial as a treatment for TNBC patients, but this regimen is quite toxic and is not 
tolerated by all patients. Also, studies have not yet explored how these results compare 
with other anthracycline/taxane sequential chemotherapy regimens. 
 In metastatic disease, Miller and colleagues compared the efficacy and safety of 
paclitaxel alone versus paclitaxel plus bevacizumab (Avastin), a monoclonal antibody 
targeting vascular endothelial growth factor (VEGF)-A as an initial treatment of HER2-
negative, metastatic breast cancer. Compared with paclitaxel alone, the 
bevacizumab/paclitaxel combination demonstrated significantly prolonged PFS (5.9 mo 
vs 11.8 mo, respectively; P <.001) and an increased objective response rate (ORR; 
21.2% vs 36.9%, respectively; P <.001). Patients whose tumors were ER- and PR-
negative had significantly improved PFS with the combination regimen than with 
paclitaxel monotherapy (8.8 mo vs 4.6 mo, respectively; HR, 0.53; 95% CI, 0.40-0.70). 
Other studies have compared outcomes using different chemotherapy agents in 
patients with metastatic TNBC. A phase III trial by Thomas and colleagues randomly 
assigned 752 patients with advanced or metastatic breast cancer who were pretreated 
or resistant to anthracycline- and taxane-based regimens to receive ixabepilone plus 
capecitabine (Xeloda) or capecitabine alone62. Overall, the ixabepilone/capecitabine 
combination was more effective than capecitabine alone in prolonging median PFS (5.8 
mo vs 4.2 mo, respectively; P = .0003) and was associated with a 25% reduction in the 
estimated risk of disease progression (HR, 0.75; 95% CI, 0.64-0.88; P = .0003). These 
results further emphasize the overall sensitivity of TNBC to standard chemotherapy 
regimens.  
In order to improve treatment options for TNBC, researchers have been extensively 
studied different molecular targets. These include molecular entities, such as 
expression of HER1 and c-Kit, mutation/perturbation of p53, activation of BRCA1-
associated pathways, namely PARP1; and activation of protein kinase components of 
the mitogen-activated protein kinase and protein kinase B (Akt) pathways35,53,63,64. In 
addition, GRB7, a calmodulin-binding protein that binds phosphorylated tyrosine 
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residues (ie, EGFR, HER2) and the small heat shock protein α-basic-crystallin (αB-
crystallin) have been associated with poor outcome among patients diagnosed with 
triple-negative and basal-like breast tumors65,66. Strategies targeting the EGFR and Src 
pathways, PARP1 inhibitors, and antiangiogenic agents are currently in clinical trials 
and are summarized in Table 2.  
 
Table I1. Stratages targeting the EGFR and Src pathways, PARP1 inhibitors and angiogenic agents   
 
  3. PROTEOMICS IN CANCER  
 
 Cancers are highly complex and are often driven by gene mutations that result in 
constitutively active signalling pathways that controle cell proliferation and growth67. 
Even though, many genome wide studies illustrated the genetic basis of cancer, they 
however, do not allow an accurate prediction of what is actually occurring at the 
protein level within a given cell at any given time. Indeed, studies focusing on 
detecting the differential expression of mRNA expression have been extremely 
informative, but they do not necessarily correlate with the protein function. 
Macromolecules, in general, and proteins, in particular, are highly dynamic 
molecules. In the other words, any protein may exist in multiple forms that can differ 
within a particular cell or between different cells. These differences can be the result 
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of translational, posttranslational, regulatory or degradation processes that can affect 
protein structure, localization, function and turnover68.  
  The deregulation of mechanisms controlling posttranslational modifications 
(PTMs) can have severe consequences. For instance, mutations in receptor tyrosine 
kinases (RTKs) can induce constitutive activation of the processes they regulate. In 
fact, many tyrosine kinases are oncogenes, and malfunctioning survival or 
differentiation mechanisms will ultimately lead to malignant transformation. Therefore, 
identification of the kinases that are active in certain tumours is indispensable, as this 
activation is not always directly caused by genetic mutation67. In-depth studying of 
proteomics profiles of various biospecimens obtained from cancer patients are 
expected to increase our understanding of tumor pathogenesis and improve the 
identification of novel targets for cancer therapy. In addition, an essential goal for 
applying proteomics to study cancers is to adapt its high-throughput tools for regular 
use in clinical laboratories for the purpose of diagnostic and prognostic categorization 
of cancers, as well as in assessing various cancer therapeutic regimens68.  
  
3.1. Mass spectrometry-based proteomics 
 
Global protein analysis poses a tough analytical challenge, in part owing to the 
highly diverse physicochemical properties of amino acids, which are the building blocks 
of proteins. Furthermore, compared to the genome, the proteome is complemented by 
alternative splicing and diverse protein modifications and degradation, and this 
complexity is further amplified by the interconnectivity of proteins into complexes and 
signalling networks that are highly divergent in time and space. Quantitative proteomics 
has been used to identify and quantify proteins in complex biological samples69. 
The classical method for quantitative analysis of protein mixtures is by protein 
separation and comparison by two-dimensional polyacrylamide gel electrophoresis (2D-
PAGE), followed by MS or MS/MS70,71. However, 2D-PAGE technique suffers from its 
inability to analyse hydrophobic, and very high or low molecular weight proteins69. 
Moreover, this technique remains a labour-intensive approach, requiring several 
different experiments for high-throughput studies. 
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To address this, non-gel-based quantitative proteomics methods have been 
developed to widen the protein dynamic range and profile69,72. These approaches utilise 
isotope-labelled compounds that are identical to the properties of their natural 
compounds except in their mass that allows for their identification in mass spectrometry. 
Stable labelling approaches include isotope-coded affinity tag (ICAT), stable isotope 
labelling by amino acids in cell culture (SILAC), isobaric tags for relative and absolute 
quantification (iTRAQ), 15N/14N metabolic labelling and other chemical labelling73,74. 
These approaches are coupled to liquid chromatography (LC) for separation before MS 
or MS/MS identification. Some limitations of the above approaches include increased 
sample preparation time, more complex methodology and higher costs attributed to 
labelling reagents69. Furthermore, simultaneous quantification using labelling methods is 
only possible between few samples69,72. Label-free quantification is an alternative to 
often costly labelling strategies in complex samples like cancer tissues. The use of this 
approach has increased enormously in the past 10 years and has shown potential for 
identification and quantification of differentially expressed proteins between normal and 




Figure I9. General depiction of various strategies in differential protein expression analysis: A is one of 
the gel-based approaches, where 2D gel electrophoresis is performed to identify differential protein 
expression on the same gel with fluorescently labeled proteins. The gel spots of interest are picked and 
in-gel digested for MS analysis for protein identification. B through D are mass spectrometry (MS)-based 
quantification approaches classified as B, metabolic; C, chemical tagging, and D, label-free approaches, 




Page 36 of 156 
	  
 
     3.1.1. Label-free protein quantification 
 
Label-free quantification overcomes the expensive and extensive workflows 
required in the labeling techniques. It is based on the correlation between peptide MS 
peak intensity and the abundance of the protein in a given sample. Regardless of which 
label-free quantitative proteomics method is used, they all include the following 
fundamental steps: (i) sample preparation including protein extraction, reduction, 
alkylation, and digestion; (ii) sample separation by liquid chromatography (LC or LC/LC) 
and analysis by MS/MS; (iii) data analysis including peptide/protein identification, 
quantification, and statistical analysis. In protein-labeling approaches, different protein 
samples are combined together once labeling is finished and the pooled mixtures are 
then taken through the sample preparation step before being analyzed by a single LC-
MS/MS or LC/LC-MS/MS experiment (Figure 11(a)). In contrast, with label-free 
quantitative methods, each sample is separately prepared, then subjected to individual 
LC-MS/MS or LC/LC-MS/MS runs (Figure 11(b)). Protein quantification is generally 
based on two categories of measurements. In the first are the measurements of ion 
intensity changes such as peptide peak areas or peak heights in chromatography. The 
second is based on the spectral counting of identified proteins after MS/MS analysis. 
Peptide peak intensity or spectral count is measured for individual LC-MS/MS or LC/LC-
MS/MS runs and changes in protein abundance are calculated via a direct comparison 




Page 37 of 156 
	  
 
Figure I10. General approaches of quantitative proteomics. (a) Shotgun isotope labelling method. 
After labelling by light and heavy stable isotope, the control and sample are combined and analysed by 
LC-MS/MS. The quantification is calculated based on the intensity ratio of isotope-labelled peptide pairs. 
(b) Label-free quantitative proteomics. Control and sample are subject to individual LC-MS/MS analysis. 
Quantification is based on the comparison of peak intensity of the same peptide or the spectral count of 
the same protein (Adopted from Zhu et al.72) 
 
For the relative quantification by peak intensity of LC-MS, an ion with a particular 
m/z is detected and recorded with a particular intensity, at a particular time. It has been 
observed that signal intensity from electrospray ionization (ESI) correlates with ion 
concentration75 . The label-free quantification of peptide/protein via peak intensity in LC-
MS was first studied by loading 10  fmol–100  pmol of myoglobin digests to nano-LC and 
analyzing by LC/MS/MS76. When the chromatographic peak areas of the identified 
peptides were extracted and calculated, the peak areas were found to increase with 
increased concentration of injected peptides. After the peak areas of all identified 
myoglobin peptides were combined and plotted against the protein amount, the peak 
area was found to correlate linearly to the concentration of protein. The strong 
correlation between chromatographic peak areas and the peptide/protein concentration 
remained when myoglobin was spiked into a complex mixture (human serum) and its 
digests were detected by LC-MS/MS. The results of quantitative profiling were further 
improved by normalizing the calculated peak areas76,77. 
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Automatic comparison of peak intensity from multiple LC-MS datasets is well 
suited for clinical biomarker discovery, which normally requires high sample throughput. 
The following studies were all performed using this label-free quantitative approach. The 
comparison of control and radiated human colon cancer cells proved the reproducibility 
of this label-free approach78; the serum proteomic profiling of familial adenomatous 
polyposis patients revealed multiple novel celecoxib-modulated proteins79; proteins 
significantly associated with metastasis were identified by analyzing paraffin-embedded 
archival melanomas80; the analysis of 55 clinical serum samples from schizophrenia 
patients and healthy volunteers identified hundreds of differentially expressed serum 
proteins81; diagnostic markers and protein signatures were recognized from the serum 
of Gaucher patients82 and the cerebrospinal fluid of schizophrenia patients83. 
In the spectral counting approach, relative protein quantification is achieved by 
comparing the number of identified MS/MS spectra from the same protein in each of the 
multiple LC-MS/MS or LC/LC-MS/MS datasets. This is possible because an increase in 
protein abundance typically results in an increase in the number of its proteolytic 
peptides, and vice versa. This increased number of (tryptic) digests then usually results 
in an increase in protein sequence coverage, the number of identified unique peptides, 
and the number of identified total MS/MS spectra (spectral count) for each protein84. Liu 
et al. studied the correlation between relative protein abundance and sequence 
coverage, peptide number, and spectral count. It was demonstrated that among all the 
factors of identification, only spectral count showed strong linear correlation with relative 
protein abundance with a dynamic range over 2 orders of magnitude85.  
 
Relative quantification by spectral count has been widely applied in different 
biological complex, including analysis of urine sample from healthy donors and patients 
with acute inflammation86, finding biomarkers in human saliva proteome in type-2 
diabetes87, comparison of protein expression in yeast and mammalian cells under 
different culture conditions88–90, distinguishing lung cancer from normal91, screening of 
phosphotyrosine-binding proteins in mammalian cells92, and identifying differential 








     Posttranslational modifications (PTMs) are key regulators of protein activity and 
involve the reversible covalent modification of proteins by small chemical groups, 
lipids or even small proteins. In addition, proteins can be cleaved by proteases, and 
the chemical nature of amino acids can be modified. Taking into account the number 
of expressed protein-coding human genes (~11,000), the array of PTMs available 
(more than 200), the number of potentially modified residues, the dynamic nature and 
the often low stoichiometry of these modifications, one realizes the magnitude of the 
analytical challenge to identify and to localize the sites of these modifications67. 
Probably owing to its ubiquitous role in almost any biological process, 
phosphorylation is still the best-characterized PTM.  Protein phosphorylation is of 
central importance in signalling systems and employed by cells to transiently alter 
protein properties such as the activity of enzymes, their interactions with other 
proteins, their localization and conformations, or to target them for destruction. When 
deregulated, it is also critically involved in disease processes, notably in cancer, 
where protein kinases are now the major class of drug targets94,95.  
  An essential step in understanding the complex molecular circuitry of cellular 
signal transmission is to develop methods for measuring the extent and nature of 
phosphorylation events that occur in a cell. For this purpose, modern quantitative 
mass spectrometry (MS) has proved to be an ideal platform because it is a highly 
precise yet generic method for the global identification and quantification of proteins 
and their modifications96–99. In eukaryotes, phosphorylation occurs almost exclusively 
on Ser (S), Thr (T), and Tyr (Y) residues, which represent approximately 17% of the 
total amino acids in an average human protein100. On this basis, there are nearly 
700,000 different potential phosphorylation sites101. In 2003, MS-based studies 
identified ~300 phosphosites, and this was considered to be breakthrough progress 
at the time; but recent MS-based studies have reported the identification of tens of 
thousands of phosphorylation sites in tissues and cultured cells102–104, and it has 
been speculated that the total extent of the phosphoproteome is more than a 
million105. This vast and increasing number of identified phosphosites raises 
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fundamental question about their properties and biological relevance and the scale of 
the complete phosphoproteome.  
 
3.2.1. Phosphoproteomics in biomarker discovery 
 
  Phosphoproteomics has been extensively used as a preclinical research tool to 
characterize the phosphorylated components of the cancer proteome. For example, 
study done by Guo et al.106 showed that growth factors and their downstream tyrosine 
kinases (e.g., Src), which are elevated during hormone-ablation therapy of prostate 
cancer, can induce tyrosine phosphorylation of androgen receptor (AR). Such 
modification may contribute to androgen-independent activation of AR or sensitize 
AR to low levels of hormone. The clinical importance of these findings is that 
inhibition of tyrosine kinases, such as Src that contribute to Y534 phosphorylation of 
AR, would be a more effective treatment regimen for hormone-refractory prostate 
cancer. Moreover, Wu et al, employed SILAC labeling based LC-MS/MS proteomic 
approaches to comprehensively profile the phosphoproteome of MCF7 breast cancer 
cells with tamoxifen resistance. Multiple crucial kinase-mediated signaling pathways 
were discovered to be hyperactivated in tamoxifen resistant cells, such as: MAPK, 
ERBB or insulin signaling pathways. Interestingly FAK2 tyrosine kinase was shown to 
play a pivotal role in development of tamoxifen resistance and potentially would be a 
very promising therapeutic target in context of resistance in breast cancer107. 
  Furthermore, identification of phosphoproteins such as kinases as cancer 
biomarkers using MS-based phosphoproteomic technologies is an emerging field. 
Nowdays, most biomarkers used in clinical studies are based on proteomic 
applications as the majority of current drug targets are proteins, such as G protein-
coupled receptors, enzymes and components of hormone signaling pathways108 (93). 
They are critically important tools for detection, diagnosis, treatment, monitoring, and 
prognosis109. Importantly, cancer-specific phosphosignatures can be used as 
diagnostic markers and/or drug targets. For instance, study done by, Goss et al.110 
identified 188 Tyrphosphorylated sites, of which 77 were novel, from six cell lines 
representing three BCR-ABL fusion types and two distinct cellular backgrounds. 
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Comparison of this Bcr-Abl signature with the profile of cells expressing an alternative 
imatinib-sensitive fusion kinase, FIP1L1-PDGFRalpha, revealed that these kinases 
signal through different pathways. This study thus, revealed novel disease and 
potential drug-responsive biomarkers in the context of BCR-ABL kinase signaling, 
and demonstrated that phosphoproteomic approaches can be useful for discovering 
drug-responsive biomarkers. 
   In triple negative breast cancer, unfortunately, the field of biomarker 
development remains immature, without clinically relevant predictive biomarkers, 
highlighting the need for biomarkers to guide therapy in the future. Thus the important 
change must be made in this field with focus on simultaneous development of 
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Triple-negative breast cancer (TNBC) accounts for only 15% of the new breast 
cancer cases but kills up to 50% of the patients suffering from this diagnosis despite the 
best standards of care and early diagnosis. This relapse rate is unacceptably high 
compared with the other breast cancer subtypes (less than 20% in long-term series).  
Gene expression or histology approaches seem to distinguish several subtypes within 
TNBC, but no clear prognostic information is drawn out of such classifications. 
Moreover, these approaches do not provide potential therapeutic solutions or suggest 
novel targets to be explored. Unfortunately, recently published “cancer atlases” have not 
found sufficient oncogenic-addiction driving alterations at the gene-code, gene-
expression or amplification/deletion level that could explain the inter-individual 
differences observed in TNBC patients population. Thus these data suggest that TNBC 
is not a single-alteration driven malignancy, but rather the result of a plethora of genetic, 
epigenetic, and microenvironmental alterations. Importantly, overall the tumour 
aberrations observed across the different layers of regulation of the tumour phenotype, 
eventually converge into discrete patterns of activation of signaling nodes. Thus we 
hypothesize that pinpointing these nodes would be a parsimonious solution for 
functional classification. Moreover such nodes, more specifically kinases, could also 
constitute potential druggable targets in TNBC. The objective of this thesis is to 
interrogate the phosphoproteome of triple-negative breast cancer cases from a 
functional point by addressing the following aims: 
1. To perform high-throughput phosphoproteomic analysis using mass-
spectrometry of triple-negative breast cancer cases in order to identify and 
quantify candidate phospho-proteins driving the aggressive nature of relapsed 
cases. 
2. To validate phosphorylation signature driving the relapsed cases in a validation 
set of triple-negative breast cancer samples by immunohistochemistry. 
3. To perform phosphoproteomic analysis of aggressive and indolent triple-negative 
cell lines in order to know whether their phosphor-profile mimics the profile found 
in relapsed vs. cured cases.  
4. Target the phosphorylation signature found to drive relapsed cases in xenograft 
model of aggressive cell lines by pharmacological inhibitors. 
OBJETIVOS 
 







































Page 49 of 156 
	  
El cáncer de mama triple negativo (TNBC), representa sólo el 15% de los casos 
nuevos de cáncer de mama pero sigue teniendo un alto indice de mortalidad de hasta 
el 50%, a  pesar de las mejoras en la  atención y del diagnóstico precoz. Esta tasa de 
recaida es inaceptablemente alta en comparación con los otros subtipos de cáncer de 
mana (menos del 20% en series de pacientes a largo plazo). Estudios de expresión de 
genes o histología han identificado varios subtipos dentro del TNBC. A pesar de ésto, 
estas clasificaciones parecen carecer de importancia desde el punto de vista pronóstico 
de la enfermedad. Por otra parte, estos enfoques no proporcionan posibles soluciones 
terapéuticas ni sugieren nuevas dianas que puedan ser exploradas. Por desgracia, el 
articulo publicado recientemente titulado  "Atlas de cáncer" no ha encontrado 
suficientes adicciónes oncogénicas que  conduzcan  alteraciones a nivel de genes, 
expresión de genes  o amplificaciónes y deleciones, que podría explicar las diferencias 
interindividuales observadas en la población de pacientes de TNBC. Por lo tanto , estos 
datos sugieren que el TNBC no es una enfermedad conducida sólo por una alteración, 
sino más bien es el resultado de un panel de alteraciones geneticas, epigeniticas y 
microambientales. En general las aberraciones tumorales se observan a través de las 
diferentes capas de la regulación del fenotipo tumoral, eventualmente convergen en 
discretos patrones de activación de nodos de señalización. Por lo tanto presumimos 
que localizar estos nodos sería una solución útil para la clasificación funcional de este 
tipo de cáncer. Por otra parte tales nodos, más específicamente kinasas, también 
podrían constituir potenciales dianas terapéuticas para el tratamiento de TNBC. 
El objetivo de esta tesis es interrogar el fosfoptoteoma de casos de cáncer de mama 
triple negativo desde un punto de vista funcional por abordar los siguientes objetivos:  
1. Hacer un análisis de fosfoproteoma de alto rendimiento usando espectrometría 
de masas usando casos de cáncer de mama triple negativo con el fin de 
identificar y cuantificar fosfo-proteínas que conducen a la naturaleza agresiva de 
los casos que recaen. 
2. Validar la señal de fosforilación que conduce a los casos de recaida en las 
muestras de pacientes de validación por inmunohistoquimica. 
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3. Llevar a cabo un análisis de fosfoproteómica en las líneas célulares triple 
negativas, tanto las que presentan un comportamiento agresivo como no 
agresivo con el fin de estudiar si presentan un patrón fosfoproteómico que 
mimetice el encontrado en los pacientes con o sin recaida.  
4. Combatir el perfil de fosforilación encontrada en los casos que recaen en 
modelos de xenograft de líneas celulares con comportamiento agresivo 
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1. PATIENT SAMPLES 
1.1. Samples for training and validation set 
   Samples from the training and validation set were gathered through the Spanish 
National Biobank Network. The study was conducted in accordance with the Declaration 
of Helsinki. Institutional review board approval was obtained at the Instituto de Salud 
Carlos III (study number: CEI PI 30-2010). For the training set 34 frozen tumor samples 
from patient diagnosed with triple-negative breast cancer were selected from three 
different Spanish hospitals (University Hospital Miguel Servet in Zaragoza, Gregorio 
Marañon Hospital in Madrid and University Hospital Complex Of Vigo) on the bases of 
biphasic relapse pattern (13 relapse within < 3 years and 21 non-relapsed after > 10 
years) with similar distribution of conventional breast cancer prognostic variables like 
tumor size (T), grade (G) and nodal status (N). None of the patients received 
neoadjuvant therapy prior to biopsy or were BRCA-1 deficient. The validation set, 113 
formalin-fixed and paraffin-embedded consecutive TNBC cases diagnosed in 2002 with 
triple-negative breast cancer were collected from two Spanish hospitals (MD Anderson 
and Hospital 12 de Octubre in Madrid). 
 
2. CELL CULTURE 
2.1. Triple negative breast cancer cell lines 
A panel of Human Triple negative breast cancer cell lines (MDA-MB-231, MDA-
MB-157, Hs578T, MDA-MB-468, HCC1937, HCC1143, HCC38, BT549, BT483 and 
MDA-MB-415) were maintained following the American Type Culture Collection 
recommendations (ATCC, Teddington, UK). Luminescent cell lines were generated by 
transfection with a plasmid encoding firefly luciferase (pGL.4.51 luciferase reporter 
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2.2. Cell proliferation assays 
Breast cancer cell lines were seeded (5x103 cells/well) in 96-well plates for 24h 
and subsequently replaced with fresh medium with vehicle (control) or serial dilutions of 
the following drugs:  2.5-20 µM A12B4C3 (TOCRIS), 0.5-5 µM palbociclib (PD0332991) 
isethionate (Selleckchem), 5-40 µM GDC-0994 (MedChem, Princeton, NJ, USA), 2.5-20 
µM imatinib (STI571) (Selleckhem), 1-10 µM LY2584702 tosylate (Selleckchem) and 
2.5-25 µM of PKC Epsilon inhibitor peptide (Cayman Chemical, Ann Arbor, MI, USA) in 
1x PBS. Inhibitory concentrations (IC50) values were determined as concentrations that 
inhibit 50% of cell viability. Viability assays were performed in triplicates, and replicates 
were normalized to cells treated with vehicle. For drug combination assays, 5x103 
cells/well were seeded in 96-well plates, left to attach for 24h and treated with IC50 of 
single compounds or combination of two compounds. After 72h cell viability was 
analyzed using CellTiter-Glo Luminescent Cell Viability Assay (Promega) following 
manufacturer instructions. For treatment combinations, the thresholds for antagonistic, 
additive, or synergistic effects were calculated as follows: DA = Da + Db (1 − Da), where 
Da is the relative inhibition (from 0 to 100%) value for the first drug and Db is the 
relative inhibition value for the second drug. Variations within ±15% of the additive 
threshold are considered to be the result of additive drug interactions; combinations 
exerting <85% of the predicted additive effect are considered indifferent (and below 
70%, antagonistic); combinations exerting >115% of the predicted threshold for additive 
effect synergistic.  
3. MICE STUDIES 
3.1. Study approval 
All animal experiments were approved by the CNIO Ethics Committee 
(PROEX/027/15) and performed in accordance with the guidelines stated in the 
International Guiding Principles for Biomedical Research Involving Animals developed 
by the Council for International Organizations of Medical Sciences. Four- to 6-week-old 
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3.2. Animal models   
For astringent model of metastasis 5x106 luciferase expressing cancer cell lines 
were suspended in 200 µl of 1x PBS (Dulbecco) and injected intraperitoneally into 
female nude mice. Bioluminescence signal was followed once per week by IVIS 
Spectrum imaging system (PerkinElmer). For mammary fat pad injections 1x106 cells 
were re-suspended in 50% Matrigel Basement Membrane Matrix  (Corning). Tumor 
formation and growth were monitored weekly by using calipers.  Tumor volumes were 
calculated using the formula V = (D °— d2)/2 mm3, where D is the largest diameter and 
d is the shortest diameter. Mice were euthanized when reaching human end point. 
Tumors were excised and fixed (10% formalin solution) for histological examination 
(FFPE) or snap-frozen for subsequent analysis. 
3.3. Treatments 
In case of intramammary injections when the tumors reached 500mm3 size, mice 
were randomized (http://www.randomization.com/) to receive either single compound or 
combinations. For intraperitoneal injections mice were randomized to receive the same 
treatment regimens two days after the injection. For the animal treatments palbociclib, 
dissolved in 50mM sodium lactate buffer, pH 4.0, was administered by oral gavage at 
100mg/kg/day. GDC-0994 was dissolved in 2% DMSO+ 30% PEG-300+ 5% 
Tween80+dH2O and administered by oral gavage at the dose of 50mg/kg/. Imatinib was 
dissolved in sterile saline and administered by intraperitoneal injection at the dose of 
70mg/kg/day.  
 Tumor growth inhibition (TGI) was calculated using the following formula: TGI = [1 − 
(TF/T0)A/(TF/T0)V] × 100, where TF is the time point analyzed, T0 is the initial time, A () 
is the tumor measurement corresponding to drug treatment , and V() is the tumor 
measurement from the vehicle treatment. 
For treatment combinations, the thresholds for antagonistic, additive, or 
synergistic effects were calculated as follows: TA = Fa + Fb (1 − Fa), where Fa is the 
relative TGI (from 0 to 1) value at a given time point for the first drug and Fb is the 
relative TGI value at the same time point for the second drug. Variations within ±15% of 
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the additive threshold are considered to be the result of additive drug interactions; 
combinations exerting <85% of the predicted additive effect are considered indifferent 
(and below 70%, antagonistic); combinations exerting >115% of the predicted threshold 
for additive effect synergistic. The effects of the combinations are calculated at the last 
time point when the animals belonging to the treatment group that was first terminated 
because of tumor growth among those compared were alive.  
3.4. Generation of PNKP knockout cells 
 
Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 All-
in One Lentivector system was purchased from Applied Biological Materials (ABM). 
Recombinant lentiviruses were generated in HEK 293T cells by cotransfection of 
sgRNA-encoding plasmids targeting human PNKP (Cat#K1676005) with pVSV-G and 




4. PHOSPHO-PROTEOMIC ANALYSIS 
All tumor samples in study had more than 75% tumor content. We interrogated the 
phosphoproteome by enriching the phospho-fraction out of 250 micrograms of purified 
protein per sample by Ti4-IMAC chromatography coupled with mass-spectrometry 
based on previous results, where we showed that this technique outperformed TiO2 and 
IMAC, other commonly used phospho-enrichment strategies111. In addition, given the 
large number of samples and the limited amount of material of the clinical specimens, 
we aimed to probe the phosphoproteome using a label-free single-shot strategy as 
described previously by de Graaf et al112. Such approach allows highly reproducible 
measurements, both qualitatively and quantitatively, over a large dynamic range112..  
One (12 samples), two (19 samples) or three (3 samples) phospho-enrichments were 
performed in the tumor samples depending on the available starting material; two and 
three phospho-enrichments were performed in 7 and 3 cell lines, respectively. Each 
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sample was run twice, for a total number of 118 (tumors) and 46 (cell lines) runs; The 
average phosphoenrichment ratio was 93.3%.  
 
4.1. Protein extraction from frozen patient tumor biopsies and triple-negative cell 
lines 
Frozen tumor samples were homogenized using a Precellys 24 device (Bertin 
Technologies, Paris, France) in ice-cold lysis buffer containing 7 M urea (ThermoFisher 
Scientific), 2 M thiourea, 2 % N-octyl glucoside (Santa Cruz Biotechnology, Inc.), 15 mM 
tris (2-carboxyethyl) phosphine (TCEP), 50 mM Hepes (pH 7.5), protease and 
phosphatase inhibitor cocktail (Halt EDTA-free; Thermo Scientific; Waltham, MA, USA), 
and 0.1% Benzonase Nuclease (Novagen, Darmstadt, Germany). 
Tumor cell lines were washed 2 times with cold PBS 1x (Dulbecco´s, Sigma-
Aldich) and harvested in ice-cold lysis buffer containing 7 M urea (ThermoFisher 
Scientific), 2 M thiourea, 2 % N-octyl glucoside (Santa Cruz Biotechnology, Inc.), 15 mM 
tris (2-carboxyethyl) phosphine (TCEP), 50 mM Hepes (pH 7.5), protease and 
phosphatase inhibitor cocktail (Halt EDTA-free; Thermo Scientific; Waltham, MA, USA), 
and 0.1% Benzonase Nuclease (Novagen, Darmstadt, Germany). 
Protein lysates from tumors and cells were sonicated for 15 min on ice and clarified by 
centrifugation at 14,100×g at 4°C for 15 min. Protein concentration was estimated by a 
colorimetric assay (660 nm protein assay; Pierce; Rockford, IL, USA) using bovine 
serum albumin as reference.  
4.2. Protein digestion, sample clean-up and Ti4+-IMAC phosphopeptide 
enrichment 
Protein samples were digested using the filter-aided sample preparation 
method113. Briefly, 250 µg of each tumor and cell line protein extract dissolved in lysis 
buffer was reduced with 10 mM DTT for 20 min at 56°C and alkylated using 50 mM IAA 
soloution for 20 min at 25°C in the dark. The excess of reduction and alkylation 
reagents were washed with 8 M urea in 100 mM Tris (pH 8). The proteins were digested 
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at 37°C in wet chamber for 4 h using endoproteinase Lys-C at a 1:50 enzyme-to-protein 
ratio. After Lys-C digestion, urea was adjusted to 2M with 50 mM triethyl ammonium 
bicarbonate. Trypsin (Promega) was added at a 1:50 (enzyme-to-protein ratio) and 
samples were subjected to a second digestion at 37°C overnight in wet chamber. The 
digestion was quenched by acidification with formic acid (0.1% final concentration). 
Prior to phosphopeptide enrichment, digested samples were cleaned up with reversed 
phase-based solid-phase extraction (SPE). Phosphopeptide enrichment was performed 
using Ti4+-IMAC GELoader spin tips by centrifugation114. Briefly, Geloader tip 
microcolumns packed with Ti4+-IMAC beads were created using a C8 plug at the 
constricted end. An aliquot of the Ti4+-IMAC beads suspension was packed in the tip at 
the ratio 2:1 of beads:peptides. Max 250µg of each digested tumor or cell line sample 
was loaded onto the column and centrifuged at 50g for 30min to allow the binding of 
phosphopeptides to the Ti4+-IMAC beads (~3 µl / min). Bound phosphopeptides were 
washed with 80% acetonitrile (ACN) in 6% trifluoroacetic acid (TFA) by centrifugation at 
170g (~3 µl / min). Afterwards two additional washing step were performed, first one 
with 50% ACN/ 0.5%TFA in 200mM NaCl and second one with 50% ACN/0.1% TFA. 
Both washing steps were performed by centrifugation at 170g (~3 µl / min). 
Phosphopeptides were eluted from the column with 10% ammonia into 25% formic acid 
(FA) and centrifugated at 100g (~1 µl / min). Finally, a second elution was carried out 
with 80% ACN/2%FA and centrifuged at 100g (~1 µl / min). Phosphopeptides were 
acidified by adding 3µl of 100% FA. The eluate was directly injected and analyzed by 
LC-MS/MS.  
4.3. Reverse Phase Chromatography and Mass-spectrometry  
Peptides were subjected to reverse phase nano-LC-MS/MS analysis using a Proxeon 
EASY-nLC 1000 (Thermo Scientific, Odense, Denmark) with an analytical column 
heater (40 °C) and an LTQ-Orbitrap Elite (Thermo Fisher Scientific, Bremen, Germany). 
Peptides were first trapped (Reprosil C18, Dr Maisch, GmbH, Ammerbuch, Germany, 3 
µm, 2 cm × 100 µm) at a maximum pressure of 800 bar with 100% solvent A (0.1% 
formic acid in water) before being separated on a 40cm x 50µm analytical column 
(Poroshell 120 EC-C18, 2.7µm, Agilent, Santa Clara, CA). Peptides were 
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chromatographically separated by a 90-min gradient from 7% to 30% solvent B (0.1% 
formic acid in ACN) at a flow rate of 100 nL/min. The total measurement time for each 
sample was 120 min. The eluent was sprayed via a distal coated fused silica emitter 
(360-µm outer diameter, 20-µm inner diameter, 10-µm tip inner diameter; constructed 
in-house) butt-connected to the analytical column. The electrospray voltage was set at 
1.7 kV. The mass spectrometer was operated in a data-dependent mode to 
automatically switch between MS and MS/MS. Briefly, survey full-scan MS spectra were 
acquired in the Orbitrap analyzer, scanning from m/z 350 to m/z 1500 at a resolution of 
60,000 at m/z 400 using an automatic gain control setting of 1e6 ions. Charge state 
screening was enabled, and precursors with either unknown or 1+ charge states were 
excluded. After the survey scan, the 20 most intense precursors were selected for 
subsequent decision-tree-based ion trap CID or ETD fragmentation115. The normalized 
collision energy for CID was set at 35%, and supplemental activation for ETD and 
dynamic exclusion were enabled (exclusion size list: 500; exclusion duration: 40 s). 
4.4. Data analysis and Kinase prediction 
The raw MS data were processed with MaxQuant software suite version 
1.3.0.5116 The fragmentation spectra were searched against the Homo sapiens Uniprot 
database (downloaded on 23-12-2013), using Andromeda as the search engine. The 
precursor mass tolerances were set to 20 ppm for the first search and 4.5 for the main 
search. Also, 0.05 and 0.5 Da were used for FT and IT detectors. 
Carbamidomethylation of cysteine was considered as fixed modifications, whereas 
oxidation of methionine (M); phosphorylation on serine (S), threonine (T) and tyrosine 
(Y); and protein N-terminal acetylation were chosen as a variable modification, and up 
to two tryptic missed cleavages were allowed. The match between run function was 
enabled. A target-decoy database searching strategy was used to evaluate the false-
discovery rates (FDRs) at the peptide and protein level.   
The identification of kinase specific substrates was evaluated using linear sequence 
motifs analysis implemented in MaxQuant116. For the identification of phosphorylated 
motifs Maxquant used the PhosphoMotif Finder search tool at Human Protein 
Reference Database was used (http://www.hprd.org/PhosphoMotif_finder)117. 
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4.5. Consensus clustering 
We applied the Consensus Clustering module using ConsensusClusterPlus 
package available in Bioconductor (http://www.bioconductor.org/) for class discovery 
and clustering validation. This method facilitates the discovery of biologically meaningful 
clusters assessing the stability for the discovered clusters by means of resampling 
techniques. Briefly, a clustering method chosen by the user is applied to each of the 
resampled data sets and, the consensus among the multiple runs, is assessed and 
summarized in a consensus matrix. This matrix is used as a visualization tool to 
estimate the cluster composition and number. For this study the Consensus Clustering 
analyses were run with hierarchical clustering algorithm, and Pearson correlation using 
500 resampling iterations. 
4.6. GO pathways 
Gene-ontology pathway analysis was performed with Enrichr: a comprehensive gene 
set enrichment analysis  (http://amp.pharm.mssm.edu/Enrichr/#)118,119. 
4.7. Differential analysis 
Differentially expressed phosphopeptides were obtained by applying linear models with 
R limma package120. (Bioconductor project, http://www.bioconductor.org). To account 
for multiple hypotheses testing, the estimated significance level (p value) was adjusted 
using Benjamini & Hochberg False Discovery Rate (FDR) correction. Those phospho-
sites with FDR <0.15 were selected as differentially phosphorylated between classes 
under comparison. Representative Heat-Map was depictured using GENE-E software.   
(www.broadinstitute.org/cancer/software/GENE-E/) 
4.8. Enrichment analysis 
Gene Set Enrichment Analysis (GSEA) was used to define set of kinase 
substrate motifs that shows statistically significant, concordant differences between 
relapsed and cured cases and aggressive and indolent triple-negative cell lines. To this 
end, GSEA was applied using annotations for motifs extracted from Perseus software. 
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Leading proteins were ranked based on their intensities. After Kolmogorov-Smirnoff 
testing, those gene sets showing FDR <0.05 were selected as significant121. 
 
5.  IMMUNOHISTOCHEMISTRY 
5.1. Preparation of tissue microarrays (TMAs) 
Tissue microarrays were mounted with 2 1-mm cores per sample (MTA-I, 
Beecher Instruments), including only the 113 samples from the validation set. An expert 
pathologist examined a template H&E slide from each sample to select the areas for 
core selection. 
5.2. Staining of TMAs with specific antibodies 
Immunohistochemical staining was performed on 5-µm TMA sections. 
Deparafinization and antigen retrieval (cell conditioning) were performed on 
DISCOVERY XT automated slide staining system using validated reagents (Ventana 
Medical Systems, Inc.,).  
The following antibodies were used for IHC: phospho-AKT (Ser473) (D9E), 
phospho-p70S6K (Thr389) (1A5), phospho-p44/42 (ERK1/2) (Thr202/Tyr204), phospho-
S6 Ribosomal Protein (Ser240/Ser244) (D68F8) and phosho-PNKP (Ser114/Thr118) 
(all from Cell Signaling Technology); CDK6 (98D/H8, Monoclonal Antibodies Core Unit, 
CNIO); PKC Epsilon [(EPR1482(2)]; PIM1 (12H8, Santa Cruz Biotechnology, Inc.), c-
KIT/CD117 (Dako), CLK-1 (Sigma-Aldrich) and DAPK3/ZIPK (LifeSpan BioScience). 
Corresponding TMA were acquired and digitalized using the Ariol SL-50 system 
coupled with fully automated microscope system Leica DM6000 B. Scores were 
generated using the TMASight assay, providing areas of high staining (Area_Color 1), 
medium staining (Area_Color 2) and low staining (Area_Color 3). We calculated the 
percentage of each staining per biopsy normalized to Area_Color 4, which represents 
the whole tissue, providing a computerized H- score calculated by formula:((% of 
Area_Color1*3) + (% of Area_Color2*2) + (%  of Area_Color 1*1))/100 
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5.3. Immunoblots 
Cells were washed 2x with PBS and harvested in cold RIPA Buffer (Sigma) 
containing 1% protease and phosphatase inhibitor cocktail (Halt EDTA-free; Thermo 
Scientific). Cell lysates were incubated at 4°C for 15 min, sonicated for 15 min and 
clarified by centrifugation at 14 000xg at 4°C for 30 min. Protein concentration was 
estimated by a colorimetric assay (660 nm protein assay; Pierce) following the 
manufacter’s instruction. 20 µg of proteins per sample were loaded on 10% SDS-PAGE 
gel and transferred to nitrocellulose membranes for further processing. 5% BSA was 
used to block the membrane for 60 min at room temperature, followed by overnight 
incubation at 4ºc with the primary antibodies. 
The following primary antibodies were used: phospho-p70S6K (Thr389), p70S6K 
phospho-p44/42 (ERK1/2) (Thr202/Tyr204), p44/42 (ERK1/2) and phosho-PNKP 
(Ser114/Thr118) (all from Cell Signaling Technology); CDK6 ready to use (clone 
98D/H8, Monoclonal Antibodies Core Unit, CNIO), PKC Epsilon (EPR1482(2), 
LifeSpan BioScience), c-KIT/CD117 (clone YR145, Milipore), PNKP (Novibio), Vinculin 
and β-Actin (clone AC-15;  both from Sigma- Aldrich). Membranes were incubated with 
appropriate peroxidase-conjugate secondary antibodies (Sigma, St Louis, MO, USA). 
Bands were visualized by the enhanced chemiluminescence (ECL) method (Lumi-
LightPlus detection kit; Roche).  
 
6. STATISTICAL ANALYSIS 
The prognostic value of each candidate kinase was calculated in two ways: with 
the Kaplan Meier method and the Log-Rank test (univariate), and with the Cox´s 
proportionate hazards model (multivariate model, adjusting the hazard ratio attributable 
to each kinase by the T and N status, age and grade), implementing a multiple 
comparisons correction to the cut-off point of P<0.05. The kinase scores were 
categorized: patients with a kinase staining above the 75th percentile were encoded as 
“1”, whereas the remainder were encoded as “0” (both for the Kaplan-Meier tests and 
the Cox models). The kinases with positive association with relapse were grouped into a 
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single variant (“K-high”); patients with a staining in one or more (positively associated) 
kinases above the 75th percentile were encoded as K-high=1; in order to be encoded as 
K-high=0, patients had to have a staining below the 75th percentile in all six kinases. 
The Kaplan-Meier method and the Cox´s proportionate hazards model were equally 
applied to investigate the K-high association with relapse (adjusted by age, grade, T 
and N status). Kinase co-linearity was investigated with the Pearson´s coefficient in a 
pairwise manner.  
  Tumor burden comparisons and survival benefit between treatment groups for 
the in vivo experiments were performed with a T-test (average burden obtained from at 
least 10 tumors per time point and condition) and the Kaplan-Meier method (used to 
compare the time-to-sacrifice between treatment groups). All tests were performed with 
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1. CHARACTERIZATION OF PHOSPHO-PROTEOMIC LANDSCAPE IN TRIPLE-
NEGATIVE BREAST CANCER  
 
Profiling breast cancer with expression arrays has become common, and it is 
believed that such studies will allow better understanding of the molecular differences 
between clinical cases, thus improving individualization of care122. However, only a 
partial concordance between genomic copy number, RNA levels and protein levels in 
both patient samples and cell lines, has been reported123–125. This can be explained, at 
least, in part, because protein levels and, in particular, phosphoprotein levels represent 
an integration of the complex genomic and transcriptomic aberrations accumulated in 
each tumour combined with translational and post-transcriptional regulation that cannot 
be fully captured by genomic and transcriptomic analysis. Protein phosphorylation is of 
critical importance in signalling systems and employed by cells to transiently alter 
different protein properties such as: protein-protein interactions, activity or degradation.  
When deregulated, it is also critically involved in disease processes, notably in cancer, 
where protein kinases are now the major class of drug targets94,95. 
In order to understand the complex network of signal transmission in triple-
negative breast cancer, it was important to develop methods that could measure the 
nature and extent of phosphorylation events that occur in particular cell. For this 
purpose, the ideal platform has provided to be modern mass spectrometry (MS). This 
technique allows highly precise, yet generic method for global identification and 
quantification of proteins and their modifications96–99. In line with this, recent mass-
spectrometry based studies were able to identify more than tens of thousands of 
phosphorylation sites in tissues and cultured cells102–105. This vast and increasing 
number of identified phosphosites raises fundamental question about their properties 
and biological relevance and the scale of the complete phosphoproteome.  
The present thesis is focused on the study of phospho-proteomic landscape of 
triple-negative breast cancer patient samples and cell lines with the aim to discover 
novel prognostic and predictive markers that could better explain different clinical 
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outcome of this aggressive subtype and moreover set the stage for the discovery of 
novel alternative targeted therapies.  
Due to the dynamic nature of the phosphoproteome, the analysis of clinical 
samples requires prudence. Several pre-analytical variables need to be considered 
when investigating phosphorylation changes within human specimens, especially when 
molecular analysis is incorporated into research and clinical practice to investigate 
prognostic/predictive signatures in biological material. Firstly, the signaling network is a 
highly dynamic system and it is deeply influenced by environmental factors such as 
stress, hypoxia and nutrient supply, thus appropriate preservation of the biological 
material is absolutely necessary for obtaining accurate and reliable measurements of 
intracellular signaling126. Secondly, the overall amount of biological material normally 
available for molecular profiling is relatively small (for example, fine needle 
aspirates/core biopsies) and cell subpopulations of interest usually represent small 
percentages of the whole tissue prior to upfront cellular enrichment. For this reason, the 
proteomic platform intended to be used for clinical and translational studies, has to 
provide high-throughput, accurate and reproducible results, even from relatively little 
starting material, such as few thousand malignant cells. 
 
1.1. Selection of technical approach for the phospho-proteomic profiling of 
TNBC cases 
 
Taking into account the importance and limited amount of biological samples we 
had available, together with desired coverage of phosopho-proteome, in the beginning 
of our study, it was essential to select the adequate technical approach to be used to 
obtain the phosphoproteomic signature of triple-negative breast cancer patient samples 
and cell lines. Moreover, it was important to determine the minimum amount of whole 
protein extract that we would need for good coverage. 
In addition, large scale phosphoproteomics strategies typically include enrichments of 
phosphopeptides due to their low abundance, using immobilized metal affinity 
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chromatography (IMAC) or titanium dioxide (TiO2) resin, followed by reverse phase LC 
coupled to electrospray ionization (ESI) tandem MS127.  Thus, since previous studies128 
showed that Ti4+-IMAC performed better in terms of the number of identified 
phosphoproteins, we decided to use this approach as  phosphopeptide enrichment 
strategy. In line with this, to test the performance of Ti4+-IMAC in samples from breast 
cancer patient biopsies and cell lines and to determine the minimal amount of protein 
extract we would need, we did phosphopeptide enrichment and subsequent mass-
spectrometry analysis testing different amount of protein extract as a starting material.  
Additionally, we tested the performance of enrichment in protein extract from HeLa cells 
and MMTV-PyMT mouse tumor sample. Using this approach we were able to identify 
different number of phospho-peptides as summarized in Figure 1. 
 
Figure 1. Number of phosphopeptides identified in samples from different origin and starting from 
different amount of protein lysate. 100µg of protein lysate from HeLa, 250µg of protein lysate from MMTV-
PyMT mouse tumour, 100µg and 250µg of protein lysate from human breast cancer tumour and 250µg of 
protein lysate from three triple-negative breast cancer cell lines (MDA-MB-468, MDA-MB-231 and BT-
549) were subjected to phosphopeptide enrichment using Ti4+-IMAC, followed by LS-MS analysis. The 
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1.2 . Identification of phosphoproteomic signature in TNBC patient samples 
and cell lines 
In order to identify phosphoproteomic signature of triple negative breast cancer 
we firstly performed phosphopeptide enrichment and subsequent LC-MS analysis and 
label-free quantification of phosphoprotein dynamics using frozen tumour biopsies from 
TNBC patients. Moreover, in our phosphoproteomic profiling we included ten triple 
negative breast cancer cell lines in order to perform therapeutic experiments, later on, 
based on their phosphoprofile. 
 
1.2.1. Phosphoproteomic profile of breast cancer cases 
For phosphoproteomic profiling of TNBC cases we collected a training set of 34 frozen 
tumor biopsies showing biphasic pattern of relapse of the disease. This training set 
included two groups of patients. One group with TNBC patients who relapsed in less 
than 3 years (Group A) and the other group with patients that were relapse-free for 
more than 12 years  (Group B). Patients in relapsed and non-relapsed group were 
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                  *Ki67 status is not a prognostic factor in TNBC129 
Table 1. Clinical and demographic characteristic of the training set 
 
Figure 2. Two sub-groups of patients were involved in training set. Group A with 13 patients that 
relapsed within < 3 years of logo-regional treatment. Group B with 21 patients non-relapsed after > 10 
years of logo-regional treatment. Kaplan-Meier curves of the training set (red) and its two subgroups. 
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Median time to relapse of group A: 17.36 months; median time to relapse of groups B: not reached (Log 
Rank P < 0.001)  
 
Our pilot study (Figure 1), in which we tested the performance of Ti4+-IMAC in 
breast cancer samples, clearly demonstrated that we were able to achieve a good 
number of identified phosphopeptides. However, it was crucial to have enough starting 
tissue material, such as no less than 250 µg of protein extract. Since, we got enough 
protein extract from all 34 frozen tumor biopsies we proceeded with Ti4+-IMAC 
phosphopeptide enrichment of all protein digests and subsequently performed LC-MS 
analysis and label-free quantification. As shown in Figure 3, different number of 
phosphopeptides were identified in breast cancer cases.  
	  	  
Figure 3. Average number of identified phosphopeptides in TNBC cases. Ti4+-IMAC was performed on 
up to minimum of 250µg of protein extract. From each breast cancer frozen tumour we performed 
minimum one enrichment. For those samples that yield more than 250µg of protein extract we performed 
replicate of enrichment.  Each enriched sample was injected at least two times in MS. Data are presented 
as average number of phosphopeptides in all the injections from each sample individually 
 
1.2.2. Phosphoproteomic profile of triple-negative cell lines  
Since the aim of our study is functional analysis and validation of potential 
therapeutic targets in animal models, together with triple negative cases, we also 
phospho-profiled ten triple negative breast cancer cell lines. Prior to phosphoproteomic 
analysis we first characterized these cell lines for their in vivo aggressive potential. For 
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this purpose ten TNBC cell lines engineered for luciferase expression were injected 
intraperitoneally into Nude mice and their survival was followed for more than 400 days. 
 Our in vivo study showed that TNBC cell lines behaved as well in biphasic 
manner. Three cell lines, MDA-MB-231, MDA-MB-157 and Hs578T, showed more 
aggressive behaviour since were able to kill 100% of animals in less than 100 days. 
However the remaining seven TNBC cell lines showed more indolent behaviour since 
animals were tumour free for more than 400 days (Figure 4). 
 
Figure 4. Summary of in vivo studies. (A) Kaplan-Meier curve of the survival of ice (N=60) injected with 
different TNBC cell lines intraperitoneally. The intraperitoneal injection is an astringent model of 
metastasis compared to tail-vein injection: the latter, compared to the former, skips the process of tumor 
cells leaving the primary site and entering the bloodstream. (B) Median time to sacrifice of animals groups 
injected with each cell lines (Log rank P< 0.001). (C) Representative images of tumor burden and 
dissemination in animals 4 weeks after injection of one of aggressive TNBC cell lines (MDA-MD-231) or 
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We were able to identify different aggressive phenotype in TNBC cell lines that 
would potentially mimic the aggressive behaviour seen in TNBC cases from our 
discovery set. 
 
Next we did protein extraction from cell lines and subsequently performed 
phosphopeptide enrichment, LS-MS analysis and label-free quantification of 
phosphoproteomic dynamics. As shown in Figure 5 performing Ti4+-IMAC enrichment 
the number of phosphopeptides that were identified in different cell lines was very 
similar (approximately 4000 phosphopeptides) 
 
 
Figure 5. Bar chart representing number of identified phosphopeptides in TNBC cell lines and HeLa 
control sample.  Ti4+-IMAC was performed on 250µg of protein extract. From each cell line we performed 
two or three enrichment experiments (replicates). For each enriched sample two injections in MS were 
performed. Data are presented as average number of phosphopeptides in all the injections belonging to 
one sample. 
 
1.3 .  Identification of differently phosphorylated peptides  
After performing phosphoproteomic analysis in both cell lines and tumour biopsis, 
in order to weight how inherently different were the cell lines-derived phosphoprofiles 
from those originated in tumor biopsies we performed consensus clustering analysis 
(Figure 6). This bioinformatics analysis involves k-means clustering resampling (x1000) 
of randomly selected profiles (from either the first or second mass spectrometry runs, 
from cell lines or tumors). The upper panel (Figure 6A) shows the visual representation 
of the relative number of times in which 2 profiles, cluster together during those 1000 
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iterations. The darker the colour is the more frequently two profiles cluster next to each 
other. In order to estimate the “real” number of clusters present in the phospho-matix, 
we plotted the area under the curve (Delta) of the consensus distribution function 
(CDF). This function shows that the optimum number of clusters is two, with a proficient 
separation between cell lines and samples (Figure 6B,C).  
 
Figure 6. A consensus clustering analysis of phosphoprofiles of TNBC tumors and cell lines. (A) A 
consensus clustering analysis was applied to weight the difference between the phosphoprofiles of the 
cell lineas and the phosphoprofiles of the tumour samples. In the figure A is the visual representation of 
almost perfect separation of two phosphoprofiles. (B)(C) As indicated in the plots the real number of 
clusters is two, which is estimated when delta area under the CDF curve is plotted for each k-means.  
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The observed difference between tumor biopsies and cell lines is highlighted in the 
Venn diagram shown in Figure 7, where approximatelly 30% of phospho-peptides were 
commonly identified in tumor biopsies and cell lines. From the proteins to which these 
phospho-peptides mapped, we performed gene-ontology (GO) analysis in order to find 
pathways enriched in each group. We found important overlap in GO pathways, even 
from non-redundant phospho-peptides, with only few pathways unique to each group 
(exp Tight junction, RNA transport). 
 
Figure 7. Venny diagram of phosphopeptides and gene ontology (GO) pathways significantly enriched in 
tumour biopsies, cell lines or both (P<0.05). 
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Even though we found interesting and important pathways in each group of 
samples, one important issue that should be highlighted is that we currently lack good 
bioinformatic tools that could integrate the status of phospho-proteins into higher level of 
information beyond GO pathways. Thus, to overcome this, we looked for differently 
phosphorylated peptides between relapsed and non-relapse patients and aggressive 
and indolent cell lines by performing differential analysis. First the log2 normalized 
phosphopeptide data from patient samples and cell lines were filtered to include 
phosphopeptides with signal in at least one sample/replicate. This analysis gave a list of 
11405 and 12257 phosphopeptides in relapsed and non-relapsed samples and 
aggressive and indolent cell lines, respectively. Furthermore, we conducted the ttest 
with permutations in order to find differently phosphorylated peptides between sample 
groups – i) early relapse and late relapse cases and ii) aggressive and indolent cell 
lines. From this analysis we found that 706 phosphopeptides were significantly 
differently phosphorylated when we compared relapsed vs. non-relapsed cases 
(FDR<0.15). Of this, 161 phosphopeptides were up-regulated (more phosphorylated) in 
relapsed vs non-relapsed cases and 545 phosphopeptides were down-regulated (less 
phosphorylated in relapsed vs. non-relpased cases). For cell lines, the same analysis 
yield in total 874 phosphopeptides that were significantly differently phosphorylated in 
aggressive vs. indolent cell lines (FDR<0.15) out of which 53 were found more 
phosphorylated and 821 were less phosphorylated in aggressive vs. indolent cell lines. 
The representative heat-map showing results of differential analysis of patient samples 
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Figure 8. Heat-Map depicturing significantly differently phosphorylated peptides in tumors (by relapsing 
status) and cell lines (by aggressiveness groups), respectively. (A) Differential analysis of phospho-data 
of patient samples showed that 706 phosphopeptides were significantly differently phosphorylated in 
relapsed vs. non-relapsed cases. Out of 706, 161 were up-regulated (more phosphorylated) and 545 
phosphopeptides were downregulated  (less phosphorylated) in relapsed cases. (B) Differential analysis 
of phospho-data of cell lines showed that 874 phosphopeptides were significantly differently 
phosphorylated in aggressive vs indolent cell lines. Out of 874, 53 were up-regulated and 821 were 
downregulated in aggressive vs. indolent cell lines. 
 
1.4 .  Kinase prediction and Enrichment analysis 
Protein kinase target substrates typically depends on the primary amino acid 
sequence proximal to the site that will be modified (Dephoure,N. et all, 
Proc.Natl.Acad.Sci.U.S.A 2008). This sequence motif can be used for the identification 
of kinase specific substrates.  In order to implement the phospho-information into further 
level of interpretation we performed motif-dependent categorization of the detected 
phosphopeptides, both in relapsed and non-relapsed cases and aggressive and 
indolent cell lines. Subsequently we applied a methodology similar to that used for 
finding Gene Set Enrichment (GSEAs)121 among clusters of interest of gene expression 
data by applying annotation of kinase motifs extracted from Perseus software, which 
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integrates 327 linear motifs (80 of which are SH2-binding domain motifs, 23 are 
phosphatase substrate motifs and 224 kinase). The enrichment plots for the kinases 
driving the profile of relapsed versus non-relapsed case and aggressive versus indolent 
cell lines are presented in the Figure 9. Figure 9A shows one sample chart of P70S6K, 
whose increased function was found in the relapsed cases on the bases of the 
abundance of its putative identified substrates, shown in the right panel.  The enriched 
kinases in the relapsed cases and aggressive cell lines are shown in Figures 9B and C, 
evidencing a further degree of overlap beyond GO pathways between tumor biopsies 
and cell lines. Interestingly besides the well-studied AKT kinase, CDK4/6130, 
CDC2/CDK1131 and PKC-Epsilon132 that were to some extent previously linked to breast 
cancer biology, the reminder have not been proposed neither as main drivers of 
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Figure 9. Kinase driving the profiles of the relapsed cases and aggressive TNBC cell lines. (A) Example 
of normalized enrichment score (NES) chart (left) for P70S6K obtained from the relative abundance of its 
phosphorylated substrates in relapsed and non-relapsed cases (right). The proteins are presented in the 
right column by their encoding gene adjacent to the site in which phosphorylation was detected. (B) The 
function of two phosphatases (DUSP6 and PP2C-delta) and ten kinases was found enriched in relapsed 
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2. VALIDATION AND TRANSLATION OF PHOSPHOPROTEOMIC SIGNATURE 
INTO A CLINICALLY ASSESSABLE TOOL 
 
Differential analysis of phospho-proteomic data revealed that out of 11405 and 
12257 phospho-sites identified by MS in TNBC patient samples and cell lines, 161 and 
53 phospho-sites were significantly up-regulated (more phosphorylated) in relapsed 
cases and aggressive cell lines, respectively. Moreover, kinase prediction and 
subsequent GSEA analysis, pointed out main kinases that potentially drive aggressive 
clinical course of TNBC. In order to ascertain that the potential novel phospho-sites and 
driver kinases identified in training set are not simply the result of an imperfect in silico 
prediction we sought for external validation in an independent patient series and 
preclinical models. 
 
2.1. Selection of antibodies for external validation 
 
So far, it is not realistic to implement mass spectrometry into daily routine clinical 
practice mainly because of poor suitability of formalin fixed paraffin embedded samples 
(FFPE, the most widely available source of tumor material as a product of standard 
tissue processing procedures followed by surgical pathology laboratories) for the 
technique133, time-to-storage-impact in the preservation of PTMs (port-translational 
modifications)134 or the cost. For that reason we aimed to translate the information 
obtained with mass spectrometry to data that could be determined in FFPE. Translation 
of mass spectrometry into immunohistochemistry could involve two main challenges. 
First challenge is the reagent availability, meaning that the antibody suitable for IHC-p is 
not always available for all detected kinases or upregulated phosphosites. Second, it is 
important to determine how we define what is an “activated kinase” and moreover how 
to detect in FFPE its active conformation. In order to select the antibodies that could be 
used to detect, in a representative way, the activated form of a kinase under study, we 




Page 82 of 156 
	  
 






Page 83 of 156 
	  
 In the first step (1) we prioritized enriched-domains over phospho-sites, since 
they integrate a broader portrait of the effector layer from the functional point of view. 
Additionally, we aimed to find classifiers that are at the same time targetable enzymes 
and for that reason the non-kinase hits we did not considered for the validation. 
Nevertheless some of the phospho-sites (2) that were found up-regulated in relapsed 
cases correspond as well to kinases and kinases are very often regulated by 
posttranslational modifications like phosphorylation. Thus, we added five kinases to 
testing workflow. However some of the enriched-domains found, corresponded to 
phosphatases (3) (DUSP6 and PP2C delta), which reflect the abundance of the 
phosphorylated substrate that is cleaved by the predicted phosphatase. If one of those 
substrates was a phosphorylated form of a kinase than this hit is added to the testing 
workflow as well. In total sixteen kinases were thus selected for the validation step. In 
cases a specific kinase had well-described, dominant and theoretically detectable 
mechanism of activation (4) (Ser 473 in the case of AKT135), antibodies against that 
targets were tested first in the pellet of tnbc cell lines embedded in paraffin with known 
status of targets by western blot ( Figure 11). Those that yielded IHC signal were tested 
in validation set. Following this workflow five hits were selected (5). For those that failed 
detection or lack the antibody suitable for IHC in human tissue, we tested non-
phosphorylated forms of the kinases (6). Additionally, three more types of kinases were 
probed with antibodies against the total proteins (6). These include, the kinases that do 
not need any further posttranslational modification for its activation (i.e. PIM136), the 
kinases which activation status is not detectable by IHC (i.e., PRKCE137,138 or KIT139,140) 
and finally the kinases which activation is driven by complex and transient mechanism 
with even opposing action (PRCKE141 or KIT142,143). We used the same validation set-up 
workflow which led to another six probes that were suitable for detection (7) and four 
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Figure 11. Validation of phospho-PNKP Ser114 in TNBC cell lines (A) Graphs showing average 
intensities of phospho-PNKP Ser114 quantified by mass spectrometry in TNBC cell lines. Mean and 
StDev were calculated from minimum 12 replicates of MS injections.(B) Western blot analysis of 
phospho-PNKP Ser114 in TNBC cell lines. (C) IHC-p with antibody against phospho-PNKP Ser114 in 
TMAs from TNBC cell lines.  
 
 
The workflow we used (depictures in Figure 10 and Figure 11) yielded 11 valid 
antibodies against the following targets: CDK6, CLK1, pS6K (Ser240), DAPK3, PRKCE, 
pAKT (Ser473), pERK (Thr202/Tyr204), pP70S6K (Thr389), PIM1, pPNKP 
(Ser114/Thr118) and cK 
 
2.2. Validation of selected phospho-sites and kinases in validation set 
In order to validate selected targets we gathered an independent validation set of 
113 consecutive TNBC patient samples embedded in paraffin from which tissue 
microarrays (TMAs) were made. Table 2 and Figure 12 shows clinical characteristics 
and survival curves of 113 patients from validation set  
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Table 2. Clinical and demographic characteristics of the validation set 
 
 
Figure 12. Validation set. Survival curve of the 113 patients from the independent validation set (black); 
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Next, we performed immunohistochemistry (IHC) on TMAs with 11 valid 
antibodies selected on the bases of workflow shown in Figure10. To acquire and 
quantify the IHC signal we used automated Leica microscope and Ariol SL-50 software. 
For each biopsy, IHC score was generated and presented as a continuous variable from 
0-3. In Table 3 and Figure 13, the IHC score distribution (in quartiles) and 
representative staining examples are shown. 
 
Table 3. IHC-scores divided in quartiles for each tested probe. 
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After obtaining IHC scores for all biopsis, in order to evaluate if validated targets 
show prognostic power, for each kinase we compared time to relapse between patients 
with high activity (the IHC score in upper quartile) versus the remainder. Out of eleven 
kinases that were predicted to have high activity in the relapsed cases of the training 
set, six of them had the ability to discriminate the clinical course in the validation set. 
This is shown in Figure 14A by the Kaplan-Meier curves and hazard rations adjusted by 
T, N, grade and age for patients that had IHC scores in upper quartile versus the 
reminder. The other five kinases did not show significant prognostic value (Figure 14B). 
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Figure 14. Kaplan-Meier curves of 113 patients divided based on presents (green) or absents (blue) of 
upper quartile staining of tested probes. (A) Represents Kaplan-Meier curves of pP70S6K (Thr389), 
PRKCE, c-KIT, pERK (Thr202/Tyr204), pPNKP (Ser114/Thr118) and CDK6, probes which upper quartile 
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staining was able to discriminate those patients that are relapsing from the others.(B) Kaplan-Meier 
curves of CLK1, PIM1,pAKT (Ser473), DAPK3 and pS6K (Ser240) which upper quartile staining did not 
pass statistical significant. The shown P values correspond to the Log-rank test for the median overall 
survival comparison. The depicted hazard ratio correspond to the adjusted hazard ratio in a Cox model by 
T, N, G and age (P<0.05). 
 
2.3. Kinomic landscape of triple negative breast cancer (TNBC): clinical 
implications 
 
We identified six kinases which high activity seem to be associated with adverse 
clinical outcome. Subsequently we wondered whether the effect of each of the six 
kinases with prognostic value was independent from the effect of the other kinases. 
With this aim, we performed linear regression analysis. As shown in Figure 15, we 
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Figure 15. Lack of significant co-linearity between six kinases with independent prognostic value. We 
performed linear regression analysis of 15 possible combinations of the 6 kinases with prognostic impact. 
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Moreover in order to see the distribution of different staining patterns of kinases 
with upper-quartile IHC-score, we sorted cases from validation set based on the 
relapsing status and presents or absents of each of six kinases. Landscape of activation 
of six kinases in cases from validation set is depictured in Figure 16.  
 
 
Figure 16. The kinome landscape of TNBC cases. Samples from validation set are ordered horizontally 
based on the status of relapse. Each of the six kinases with prognostic power are listed on the left had 
side of the grid. The presents of activated kinase is highlighted with different color, PRKCE (red), P70S6K 
(dark blue), PNKP (yellow), ERK1/2 (orange), cKIT (light blue) and CDK6 (purple) so in this way the 
number of activated kinases per patient is depicted.   
 
 
After obtaining the grid we could observe clear aggregation of activated kinases 
in the relapsed cases with several different staining patterns of kinases with upper-
quartile staining IHC scores. Interestingly we found only two patients in the relapsing 
group that did not have kinases in upper-quartile IHC scores. Ability to identify patients 
who, after standard chemotherapy treatment, could be effectively treated compared with 
patients who might need different therapeutic regiment relapse seams indeed tempting. 
Thus we examine the outcome of patients whose tumors show high activity of any of six 
kinases versus the remainder. The resulting combined variable (herein “K-high”) 
allowed division of the 113 patients in two groups. Former with 81 patients (71%, which 
tumors show high activity of any of six kinases) and latter with 32 patients (29%, which 
tumors show low activity of six kinases). The relapse rate were 47% and 7%, 
respectively, after more that 12 years of follow-up. Respective median time to relapse 
were 9.9 years and not reached (P<0.001) (Figure 17). After adjusting for T, N, G and 
age, K-high showed a hazard ratio for relapse of 9.22 (P=0.002).  
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Figure 17. Kaplan-Meier curve for combined variable (“K-high”). Relapse of patients whose tumors show 
high activity of any of 6 kinases (green; K-high=yes) versus the rest of the patients from validation set 
(blue; K-high=no).  
 
 
Interestingly the number of activated patterns per patient, as it could be observed 
in the grid (Figure16), shows important variation. Out of 64 possible patterns we found 
only 38 listed in Table 4. Twelve of them were exclusive for relapsed cases. However 
majority were present in very few cases. The most observed pattern was lack of 
activation of any of six kinases and this pattern was present in most of cured cases (29 
patients). The other very common pattern was activation of single kinases (c-KIT or 
CDK6). Nevertheless great number of patterns involved combination of two or more 
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Table 4. Kinase activation patterns found in the validation set. For each pattern the description of its 
components (activated kinases), the total number of patients and number of cases with each patter that 
are cured (0) or relapsed (1) is depicted in the table.  
 
2.4. In vitro validation of kinases defining the TNBC landscape  
 
By mass spectrometry we identified and quantified peptides that are 
phosphorylated as a result of the hyperactivation of the six kinases. Most likely this 
hyperactivation of the kinases is a consequence of a genetic evolution process, and for 
that reason kinases might be used as de facto targetable drivers. In order to test 
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weather any of six kinases could be used as targets for triple-negative breast cancer we 
conducted in vitro experiment in 10 triple-negative breast cancer cell lines. Firstly we 
estimated IC50 of drugs against each of the six kinases. We purchased A12B4C3, 
palbociclib, GDC-0994, imatinib, the peptide-EAVSLKPT-OH and Ly2584702 against 
PNKP, CDK6, ERK, c-KIT, PRKCE and P70S6K, respectively. As shown in Figure 18A 
and B, most of the single-agent treatments in each of the ten triple negative cell lines 








Figure 18. (A) Efficacy of single agents targeting the signaling nodes in K-high. Cell survival of ten triple-
negative cell lines after treatment with increasing concentrations of six against (A12B4C3, H-EAVSLKPT-
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Figure 18. (B) Efficacy of single agents targeting the signaling nodes in K-high. Cell survival of ten triple-
negative cell lines after treatment with increasing concentrations of six against (A12B4C3, H-EAVSLKPT-
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However the lack of co-linearity between activated kinases (Figure15) and the 
observed trend toward aggregation of activated kinases in the relapsed cases 
(Figure16), made as thinking that probably additional effect of more than one kinase is 
necessary to maintain the behavior of the relapsing phenotype. For that reason we 
designed 2-by-2 drug combination pairs (15 pairs in total) to test in ten triple negative 
cell lines. Among 150 test combinations, 0 (0%) were antagonistic, 1 (0.7%) was 
additive, and 149 (99.3%) were supra-additive (Figure 19A and B). MDA-MB-468 cell 
lines treated with combination of PNKP inhibitor and PRKCE inhibitor peptide was the 
only combination showing the effect within additive boundaries. 
 
 
Figure 19. (A) Therapeutic synergism of inhibiting the driving kinases of TNBC in 4 of 10 triple-negative 
cell lines. Relative cell viability of each of 4 triple-negative cell lines after 72h of exposure to each of the 
compounds alone or the 15 possible combinations compared to vehicle alone (100%). Drugs were 
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applied at the concentrations as indicated in the figures. The percentages presented in red highlight if the 
value is beyond the limits of the additive effect.   
 
 
Figure 19. (B) Therapeutic synergism of inhibiting the driving kinases of TNBC in 6 of 10 triple-negative 
cell lines. Relative cell viability of each of 6 triple-negative cell lines after 72h of exposure to each of the 
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compounds alone or the 15 possible combinations compared to vehicle alone (100%). Drugs were 
applied at the concentrations as indicated in the figures. The percentages presented in red highlight if the 
value is beyond the limits of the additive effect.   
 
2.5. Validation of effective drug combinations in vivo   
 
After showed supra-additive effects of drug combinations in cell lines we next 
proceeded to validate this further in in vivo animal model. We selected one of the 
aggressive cell lines MDA-MB-231 for orthotopic xenograft model on the bases of 




Figure 20. Therapeutic targets - levels of the 6 kinases of the signature in the cell lines. Immunoblots of 




Page 101 of 156 
	  
For orthotropic mouse model, tumors were allowed to grow proximally up to 500 
mm3 and then the animals were randomized to receive single agent or combination of 
two regiments (n>6 tumors per group). Since specific inhibitor for PNKP has not been 
tested yet for animal experiments, to avoid off-target effects and unknown 
pharmacodynamics and pharmacokinetics we decided to use CRISPR–Cas9 
technology with small guiding RNA targeting PNKP (sgPNKP). We first verified efficient 
down- regulation of PNKP protein expression in MDA-MB-231 cell lines  (Figure 21).  
 
Figure 21. Immunoblotting of cell lysate from MDA-MB-231 cell line introduced with CRISPR construct. 
 
Next the cells containing sgPNKP were injected into mammary fat pad and 
allowed to grow up to 500mm3. Then the animals were randomized to receive vehicle or 
indicated drug combinations. Figure 22 A and B shows the tumor growth inhibition and 
tumor burden that we followed for 2 weeks. Our in vivo data indicate that single agent 
treatment show modest effects on tumor growth. The tumor growth inhibition was 35.5 
with ERK inhibitor (GDC-0994), 20.8 with cKIT inhibitor (imatinib), 39.6 with CDK6 
inhibitor (palbociclib) and 25.6 in case of tumors with downregulation of PNKP 
(sgPNKP). However combinatory treatments show significant decrease of tumor growth 
compared to single treatments. Tumor growth inhibition was 70.2 (imatinib plus GDC-
0994), 90.0 (palbociclib plus GDC-0994), 55.3 (sgPNKP+imatinib) and 56.8 
(sgPNKP+GDC-0994) at T=2 weeks. This inhibitory effect is further highlighted when 
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Figure 22. Validation of selected targets in animal models of breast cancer. (A)Tumor growth inhibition 
was, respectively, 35.5 (GDC-0994), 20.8 (imatinib), 39.6 (palbociclib), 25.6 (sgPNKP), 70.2 (imatinib plus 
GDC-0994) and 90.0 (palbociclib plus GDC-0994), 55.3 (sgPNKP+imatinib), 56.8 (sgPNKP+GDC-0994) 
at T=2 weeks.  P values are indicated in the figure. (B) Shows tumor burden charts at T=2 weeks. P 
Values are depicted in the figure. Error bars: SEM. 
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 The clinical and molecular heterogeneity of breast cancer is well known. The 
advancement and widespread application of 'omics' technologies (genomics, 
epigenomics, transcriptomics or proteomics, among others) has provided 
unprecedented insights and novel understanding of the molecular complexity of this 
disease48,144–147. In spite of this complexity, clinical decisions still rely primarily on the 
assessment of three markers: the expression of the endocrine receptors for oestrogen 
and progesterone (ER and PgR, respectively) and the aberrant expression of HER2. 
The definition of triple-negative breast cancer (TNBC) applies to all tumors that lack the 
expression of ER, PgR and HER2, all of which are molecular targets of therapeutic 
agents148. 
Exploring novel approaches to treatment of these subtypes is critical because 
less than 30% of women with metastatic breast cancer survive five years and virtually 
all women with metastatic TNBC will ultimately die of their disease despite systemic 
therapy. To date, not a single targeted therapy, beyond PARP inhibitors for the 
BRCA1/2 mutated cases148, has been approved for the treatment of TNBC and 
cytotoxic chemotherapy remains the standard treatment.149 
The introduction of high-throughput technologies that survey thousands of genes 
and their products in a single assay, coupled with powerful analytical tools, has opened 
up new avenues for classifying triple-negative breast cancer into biologically and 
clinically distinct groups based on gene expression patterns 15,17, DNA copy number 
alterations 147, miRNA expression profiles {Dvinge, 2013 #2} with endnote. Next-
generation sequencing (NGS) studies have produced knowledge about this disease and 
pinpointed novel drivers of TNBC 144,146, however disease segmentation narrowing 
down the classifiers to the top-29 mutated genes leads to unique set of mutations at the 
protein level146. Despite the efforts of gene-based high-throughput techniques, previous 
data, unfortunately, have not led to precision-medicine tools yet.   
Patient classification tools should not only accurately predict a patient’s clinical course 
but also provide therapeutic solutions. These results are difficult to achieve because of 
the nature of high-throughput studies. For instance, the fine-tuning of gene-expression 
patterns is technically and conceptually challenging. NGS studies have defined cancer 
DISCUSSION 
 
Page 106 of 156 
	  
subtypes by point mutations, which are actionable targets in several malignancies, but 
not in breast cancer145. Highly penetrant oncogenes are rarely found in breast cancers, 
except for HER-2 amplification, which suggests that the "TNBC phenotype" is the result 
of coexisting, moderately penetrant, genetic changes. A prognostic stratification system 
directly linked to different therapeutic options is needed for TNBC. 
Despite the recognize heterogeneity, TNBC can be simplistically reduced in two clinical 
subtypes. Tumors of those patients that relapse within 3 years after treatment for 
logoregional disease, and tumors of other patients, who, with few exceptions rarely 
relapse31.  
This doctoral thesis aimed to understand further the TNBCs classified by 2 patterns of 
relapse focusing on discovery of new prognostic and/or predictive markers and novel 
therapeutic solutions for patients with adverse tumor characteristics. To achieve this aim 
we chose less commonly used investigation approach named high-throughput 
phosphoproteomics. This approach was selected firstly because proteins are the 
“effector molecules of tumor cells150–154 and secondly, the functional status of proteins is 
modulated through post-translational modifications (PTMs), of which phosphorylation is 
the most important150–154. The investigation of tumour behaviour by assessing "lower-
level -omics" (genomic or transcriptomic profiles) ignores the "upper-level" (proteome) 
regulatory events155,156; thus, interrogating the proteome, and, in particular its PTMs, 
might provide a more accurate and functional assessment of tumour behaviour. 
Phosphoproteomic analysis is plagued by the same challenges facing all proteomic 
experiments: complexity, dynamic range, and temporal dynamics. The true complexity 
of the phosphoproteome has yet to be determined, but the Phosphosite database 
(http://www.phosphosite.org) now lists 30 000 phosphorylation sites on 17 000 proteins, 
and this number is steadily increasing as each large-scale phosphorylation analysis 
continues to identify a large number of novel sites. With so many of the proteins in the 
cell being phosphorylated, the dynamic range of the phosphoproteome is similar to that 
of the proteome (i.e., 1x109), but is further increased by substoichiometric modification. 
In addition, the temporal dynamics of protein phosphorylation regulate the rapid 
activation and deactivation of cellular signaling networks, further complicating analysis 
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of the phosphoproteome. So the challenge is not simply to identify and catalog all of the 
phosphorylation sites, but rather to identify the site, quantify the stoichiometry, and 
monitor the temporal change in phosphorylation in response to a variety of cellular 
perturbations. Performing this task on a large number of phosphorylation sites across a 
broad swath of the signaling network is especially challenging, but is required to 
understand the mechanisms by which protein phosphorylation controls cell biology122.. 
The application of new proteomic techniques for phosphopeptide quantification is 
contributing to an improved understanding of cancer cell biology 157–160. Several 
techniques for quantitative proteomics have been developed; these can be divided into 
those that require labeling of proteins with stable isotopes (for example, SILAC and 
iTRAQ) and those that do not require labeling 161,162. Approaches based on labeling 
techniques usually detect a larger number of phosphopeptides than those based on 
label-free approaches because labeling techniques are compatible with extensive 
fractionation prior to mass spectrometry analysis. However, because of the time-
consuming nature of such analyses, studies based on labeling techniques normally 
compare a small number of samples with no (or very few) biological replicates, a feature 
that limit the statistical significance of the results. Therefore there is a trade-off between 
the number of peptide/proteins identified and samples that can be compared in a study. 
Label-free approaches are preferred when the aim is to compare large sample numbers 
and replicates 163even though the penetrance of the approach may not be as large as 
when using techniques that allow extensive fractionation before mass spectrometry 
analysis. Aiming for large sample number analysis we decided that label-free approach 
is better option for quantification of phosphoproteins in our study. Due to the fact that 
analysis of phosphoproteom is very demanding164, prior to initialing such study in tumor 
biopsies of training set, we first performed few pilot studies involving different sample 
types. We assessed the performance of Ti4+-IMAC phosphopeptides enrichment 
strategy in samples from different origin and with different amount of staring material. 
The number of phosphopeptides in human cell lines and biopsies, and mouse tumor 
varied depending on the amount of protein material used (Figure 1). We identified ~ 
3000 phosphopeptides, in HeLa control sample from 100 µg of protein extract, which is 
similar as previously shown by Zhou H et all104 using the same enrichment strategy. 
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Moreover in the breast cancer cell lines the number of identified phosphopeptides was 
near 5000 staring from 250µg of protein extract. Increased number of phosphopeptides 
was expected since the amount of starting material was also higher.  The number of 
phosphopeptides we identified in human biopsies was very similar to the HeLa control, 
3000 phosphopeptides, starting from 250µg and only ~500 from 100µg of proteins. 
Complexity of human tissue complicates the performance of phoshoproteomic 
strategies, which could explain the lower number of identifications in tumor biopsies 
compared to cell lines. Since our pilot experiment yielded ferly good results and gave us 
a global insight regarding number of phosphopeptides that could be identified with 
selected approach in tumor biopsies and cell lines we proceeded toward high-
throughput phosphoproteomic analysis of 34 triple-negative samples from training set 
and 10 triple-negative cell lines. 
 
1. IDENTIFICATION OF PHOSPHOPROTEOMIC SIGNATURE DRIVING 
RELAPSING CASES AND AGGRESSIVE CELL LINES. 
 
The mammalian cell constantly receives signals from its surroundings to which it has 
to respond appropriately. For example, growth-factor signals are integrated with 
internal-state information and lead to decisions on cell growth, differentiation, or 
proliferation165–167. Many human diseases, including multiple forms of cancer, arise 
through deregulation of this processing. In last couple of decades, our knowledge of the 
players in signal transduction mechanisms has been accumulated, mainly through the 
study of individual molecules in specific pathways. More recently, the emergence of 
technologies allowing high-throughput experiments such as microarray analysis, has 
provided a detailed and objective view of downstream transcriptional changes following 
various stimuli. However, many critical events involved in cellular responses are 
mediated by changes in posttranslational protein modifications rather than 
transcriptional changes168. A central deficiency in our knowledge of cancer concerns 
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As preciously mentioned triple-negative breast cancer (TNBC), can be simplistically 
reduced to 2 clinical subtypes: tumours of those patients who relapse within 3 years 
after treatment for locoregional disease, and tumours of the other patients, who, with 
few exceptions, rarely relapse31. Interrogating the proteome, and, in particular its PTMs, 
might provide a more accurate and functional assessment of tumour behaviour. We 
hypothesized that all the existing (genomic, transcriptomic, etc) aberrations across 
different patients might converge into a discrete number of phosphorylation-driven 
patterns of activation of the proteome that would account for the 2 main clinical 
subtypes of TNBC. These patterns would be driven by some of the ~500 kinases 
encoded by the human genome, and the kinases might be targetable by any more then 
200 available   clinical-grade inhibitors. Our aims were: to 1) define the phosphoprofiles 
that could differentiate the relapsed cases from the remainder, 2) identify the 
hyperactive kinases driving these profiles, 3) translate this information into an 
application that could be usable in a routine clinical environment, and 4) investigate the 
usefulness of driver kinases as therapeutic targets. In order to achieve our specific aims 
we collected a training set of 34 TNBC patients divided in two groups (A and B) based 
on biphasic pattern of relapse. Of these 34, 13 (group A) were early relapse patients 
and 21 (group B) late relapse patients (Table1, Figure 2). Moreover in order to later 
validate our findings in in vivo/in vitro setup we characterized collection of 10 tnbc cell 
lines for their aggressive phenotype and preformed phosphoproteomic analysis seeking 
for matching phospho-signatures. We used astringent model of metastasis, 
intrperitoneal injection, since the intra-tail vein avoids the process of tumor cells leaving 
the primary site and entering the bloodstream171. As shown in Figure 4 our in vivo study 
clearly distinguished two groups of cells line - aggressive and indolent, thus mimicking 
biphasic pattern of relapse behaviour in patients. Three cell lines MDA-MB-231, MDA-
MB-157 and Hs578T showed more aggressive behaviour since the animals injected 
with this cell lines survived less than 100 days. The rest of the cell lines showed more 
indolent behaviour since the animals survived for more than 400 days. As previously 
demonstrated by Prat et al., the three cell lines with aggressive behaviour, have a gene 
expression pattern similar to the claudin-low tumor subtype compared to the other 
seven cell lines which had gene-expression patter similar to basal-like tumors. In terms 
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of prognosis, claudin-low tumors showed worse prognosis compared to other 
subtypes.17 Moreover recently the study published by Lehmann et all where the authors 
analyzed gene expression profiles from more than 500 TNBC cases, reported 6 
different TNBC subtypes. Two of the subtypes, a mesenchymal (M) and mesenchymal-
stem-like (MSL), were enriched in gene expression for epithelial-mesenchymal 
transition and growth factor pathways and correlated with gene expression of three 
aggressive cell lines. In the same study the authors showed that the patients with the M 
and MSL subtype had decreased 5-year survival, consistent with enrichment in 
pathways associated with metastasis and motility172. Thus, the aggressive behavior of 
MDA-MB-231, MDA-MB-157 AND Hs578T observed in our in vivo experiment is in 
agreement with previous studies and could be explained by their different genetic 
features.   
Next we did consensus clustering of phosphoproteomic tumor and cell lines 
profiles and observed a separation between the nature of the phosphopeptides 
identified in tumor biopsies and cell lines  (Figure 5). This difference in 
phosphoproteomic profile is not that surprising, since we preformed the analysis on 
established cell lines, which to some extant mirror all the heterogeneity associated with 
clinical samples. Moreover, complex inter-relationships that exist between cells within 
the tumor are lost when cell lines are cultured on plastic in two dimensions. Despite this, 
two-dimensional culture system, still remains the most favored mechanism for in vitro 
studies in breast cancer research. In addition, cell lines are often sensitive to culture 
conditions - particularly the inclusion of growth factors that can sometimes alter the cell 
phenotype, resulting in inappropriate pathway activation or differentiation173,174. The 
Venny diagram shown in Figure 7 highlights these differences, with ~1/3 of the 
phosphosites commonly quantified in tumor biopsies and cell lines. However, gene 
ontology (GO) analysis performed for the proteins to which identified peptides were 
mapped, showed enrichment in common pathways with very few GO pathways unique 
to either the cell lines or the tumor samples Figure 7. Some of the common pathways 
identified were tight junction, focal adhesion and insulin signaling pathway, that have 
been already described during the process of adaptation of tumor cell to tissue culture 
conditions175. Although indicating that even from the non-redundant phosphopeptides it 
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is possible to find the enrichment in common pathways in tumor biopsies and cell lines, 
this analysis does not consider the functional regulation exerted by the process of 
phosphorylation. As a matter of fact protein modification sites can serve as nano-
switches in the distributed biochemical network of the cell. These switches control the 
flow of information through a particular protein, or node, of the network, helping to 
shape dynamic biological processes including genetic silencing, cellular growth, 
differentiation, and apoptosis176. Thus to integrate phosphopeptide status into 
functionally relevant readouts we performed differential analysis within tumor biopsies 
and cell lines. The heat-map in Figure 8A shows the 706 peptides identified in tumor 
biopsies that manifested significantly differential regulation, out of which 161 were 
hyperphosphorylated in the relapsed cases than in non-relapsed ones. Interestingly, 
when we searched in the literature for these phosphosites, 63 of them still have not 
been associated with breast cancer. This highlights the need to conduct the research at 
this layer of regulation not only for knowledge generation but also because it has been 
shown that phosphorylation of different sites could be associated with activation of 
specific nodes177,178. Differential analysis in cell lines illustrated with heat-map in Figure 
8B showed that 874 peptides, presented significantly differential regulation. Moreover, 
only 53 peptides were found hyperphosphoryated in the aggressive cell lines compared 
to indolent ones.  Despite the lack of information on the functional description and 
annotation of many of the identified phosphosites, we sought to interpret the information 
on phosphosites that we had obtained at a deeper level. From the identified 
phosphoprofiles we predicted kinases, based on the nature and abundance of 
phosphorylation events and theoretical affinity of the consensus sequence for each 
kinase. Furthermore, we preformed gene set enrichment analysis121 of kinase motifs 
and we generated enrichment plots for the kinases driving the profiles of relapsed 
versus non-relapsed cases. Figure 9A shows a chart for kinase PP70S6K, for which 
increased activity was predicted for the relapsed cases based on the abundance of its 
substrates. Kinase set enrichment analysis (KSEA) also pinpointed to additional 10 
kinase motifs enriched in the aggressive cases. Moreover, the same study preformed in 
cell lines yielded 3 kinase motifs, PAK2, PRKCE and PIM1, enriched in aggressive cell 
lines, which were also found in relapsed cases (Figure 9B, C). This result could indicate 
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some degree of overlap between tumors and cell lines beyond gene ontology (G0) 
pathways. With the exception of AKT, CDK6, CDK1 and PRKCE, the other kinases 
have not been previously proposed as drivers of adverse clinical behavior or potential 
therapeutic targets in TNBC yet. For example overexpressed pAKT was found 
frequently observed in human lung, gastric, hepatocellular, pancreatic, renal, prostate 
and endometrial cancer as well as multiple myeloma179–182. Studies have documented 
the prognostic role of pAKT overexpression in some cancers. A recent meta-analysis 
showed that pAKT overexpression was significantly associated with worse overall 
survival in non-small cell lung cancer patients (hazard ratio [HR]: 1.38, 95% confidence 
interval [CI]: 1.11–1.70)183. Thus, our finding about the activation of AKT kinase is 
consistent with the observations in other solid tumors.  In the study of Nakanishi et al 
where authors looked at 135 hepatocellular carcinoma patients, multivariate analysis 
identified pAKT overexpression as a strong predictor for early disease recurrence 
(relative risk: 12.5, 95% CI: 2.59–60.55) and poor prognosis (relative risk: 7.90, 95% CI: 
1.25–50.00)180. The study of Cinti et al in 50 advanced gastric carcinomas showed that 
the five-year survival rate was 18% in the patients with pAKT overexpression versus 
58% in the pAKT-negative ones184. These findings together with ours suggest that pAKT 
overexpression could be a common driver shared by multiple types of human cancer, 
and thus it has the potential for being a therapeutic target of great clinical significance. 
Moreover, study done by Hsu et al support our findings since they also linked CDK4/6 
as a driver of TNBC. In their study they found eight TNBC-related kinases to be 
overexpressed in TNBC cell with stem-like properties. Among them, expression of PKC-
a, MET, and CDK6 in tumor biopsies correlated with poorer survival outcomes. In cases 
coexpressing two of these three kinases, survival rates were lower than in cases where 
only one of these kinases was expressed. In functional tests two-drug combinations 
targeting these three kinases inhibited TNBC cell proliferation and tumorigenic potential 
in a cooperative manner. A combination of PKC-a-MET inhibitors also attenuated tumor 
growth in a cooperative manner in vivo185. Another study done by Xia et al analyzed 
CDK1 as a potential target in breast cancer. The authors investigated CDK1-mediated 
phosphorylation of BRCA1 and suggested that a reduction of the CDK1 activity by small 
molecule inhibitors improved the response to PARP inhibition in vitro, and served as a 
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guide to translate this to substantial antitumor activity in vivo131. PRKCE was also 
previously linked as a driver of TNBC. Data from the cancer genome atlas suggested 
increased copy number of PRKCE in this adverse subtype of breast cancer. Dann et all 
showed that overexpression of PKCε in a non-tumorigenic breast epithelial cell line is 
sufficient to overcome contact inhibition and results in the formation of cellular foci. 
Correspondingly, inhibition of PKCε in a TNBC cell model results in growth defects in 
two-dimensional (2D) and three-dimensional (3D) culture conditions and orthotopic 
xenografts132. Thus together with studies previously mentioned, our study highlights that 
specific kinasis have a very important role in TNBC and are very promising targets for 
therapeutic intervention. 
 
2. TRANSALTION INTO CLINICAL ASSESSMENTS AND EXTERNAL VALIDATION  
In order to rule out that our results were not caused by an imperfect in silico algorithm, 
we sought external validation by analyzing an independent patient series and preclinical 
in vitro and in vivo models. 
The translation of mass spectrometry into routine clinical practice is currently not 
straightforward, because of a variety of unresolved issues, including the unsuitability of 
formalin-fixed paraffin-embedded samples (FFPE) for the technique133, the effect of time 
until sample storage on the maintenance of PTMs134, the logistics of this type of 
assessment, and cost. So far, two inherent obstacles are usually associated with FFPE 
tissue proteome initiatives; limited protein extraction due to poor solubility and 
ambiguous protein identification due to possible unknown peptide modifications. Since 
formaldehyde is a highly polar compound, a set of complex protein–protein and protein–
nucleic acid cross-links are likely to be formed186,187. While this covalent complexity 
preserves the cellular morphology, it constrains sample processing logistics by the less 
amenable solubility and resistance to a variety of extraction buffers188,189.Thus, we 
aimed to translate the information that we obtained by mass spectrometry into data that 
could be obtained from FFPE samples, while seeking external validation for our results. 
"Mass spectrometry-to-immunohistochemistry translation" involves 2 main challenges: 
1) lack of suitable reagents, meaning that antibodies suitable for use in the 
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immunohistochemical detection of most of the kinases or upregulated phosphosites 
identified by phosphoproteomics are not available; 2) unknown criteria for defining an 
"activated kinase" and identifying the activated form in FFPE samples. Using the 
algorithm depicted in Figure 10 together with in vitro confirmation of the utility of each 
antibody (Figure 11) we selected the antibodies that we employed for external validation 
of the hits depicted in Figure 9. This workflow yielded 11 valid antibodies against the 
following targets: CDK6, CLK1, pS6K (Ser240), DAPK3, PRKCE, pAKT (Ser473), pERK 
(Thr202/Tyr204), pP70S6K (Thr389), PIM1, pPNKP (Ser114/Thr118) and c-KIT. The 11 
targets were stained in an independent set of TNBCs of 113 patients which clinical and 
demographic characteristics and Kaplan-Meier curve are presented in Table 2 and 
Figure 12, respectively. Advantages of automated IHC measurements over pathologist	  
visual scoring are precision in ranges of staining that appear weak to the eye190 and 
production of continuous data. Moreover, when automated IHC measurements are 
provided to a pathologist during visual scoring, computer-aided IHC analysis 
substantially improves both intra- and inter-observer agreement191. For these reasons 
we selected automated quantification of the positive staining and generation of IHC-
scores for each antibody. IHC-scores we than divided into quartiles (Table 3, Figure13) 
for subsequent prognostic analysis. We considered a kinase of interest “highly active” if 
IHC-score was in the upper quartile. When using upper quartile staining, for each 
kinase, to stratify patients by their time to relapse we found that 6 out of 11 kinases 
were able to predict the clinical course of patients in the validation set, as shown by 
Kaplan-Meier curves and the hazard rations (Figure 14), which were adjusted by T, N, 
grade (G) and age. These results appear to be mostly novel since reports linking any of 
the 6 kinases to prognosis or therapeutic potential in TNBC are very scars. ERK has 
been reported to be associated with bad prognosis and suggested as a potential target. 
For example Bartholomeusz et all showed that high ERK (ERK-2 and pMAPK) 
expression is an important predictor of OS and disease-free survival outcomes in 
patients with TNBC and suggested that ERK expression may be the driving force in 
TNBC192.	   This is also in agreement with study done by Fujii et all where the authors 
concluded that ERK has a pleiotropic role in gene regulation by controlling the 
phosphorylation of transcription factors, including Elk-1, and chromatin remodeling via 
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EZH2 and histone H3 methylation. These effects seemed to be critical to the 
aggressiveness and high growth rate of triple-negative breast cancer193.  
In the case of other kinases such as CDK6, as mentioned previously  Hsu et all reported 
that high CDK6 function as a potential factor for adverse clinical course185, while the 
reports regarding its potential role as a target in TNBC are contradictory185,194. Similar 
results we found for the c-KIT, where Burtain et all reported the amplification of c-KIT in 
a subgroup of TNBC patients with a intermediate prognosis195, (while no positive results 
as a potential target exist). However, PNKP, PRKCE and P70S6K protein have not 
been linked yet to either prognosis or targetability in this disease. Finally lack of 
significant co-linearity between kinases (Figure 15) and discrete number of activated 
patterns (Figure 16) per patient leaded us to investigate prognostic information of 6 
kinases together. When one or more of them concurrently co-exist, the relapse risk 
increases greater than 9-fold risk of relapse, even when adjusted for the conventional 
risk factors (Figure 17). Eventhough each of the 6 kinases confers on itself clinically 
useful information  (Figure 14), the lack of relapse in a group of patients without any of 
the 6 kinases active, allowed us to detect which of the signalling nodes seam to be 
sufficient to maintain the biology of the aggressive cases. According to the status (high 
activity or not) of the kinases in the tumours from the validation set, we observed two 
main patterns. One, without high activity among any of the 6 kinases that was 
associated with a very high long-term relapse-free rate. From the clinical point of view 
the ability to identify patients belonging to this group is very important, since therapeutic 
efforts could be focused on other patients not in this group. The second pattern (with 37 
sub-patterns) was characterized by the hyperactivity of one or more kinases; all but two 
of the patients who developed relapse had tumours showing this pattern (Figure 16, 
Table 4). These results suggest that the activation of any of these kinases was sufficient 
to cause an aggressive clinical course. To the best of our knowledge, we are not aware 
of any other prognostic tool that can stratify the outcomes of patients with TNBC with 
the accuracy of K-high. Interestingly, the 6 kinases of K-high can be measured rapidly 
and inexpensively. More importantly, in the context of the lack of drivers of oncogene 
addiction in TNBC, our strategy narrows down the potential millions of two-by-two drug 
screening combinations of currently existing targeted drugs, to a 15 possible 
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combinations with agents that target those 6 targets for TNBC patients that are not 
cured by the current standard of care. The 15 drug combinations, which were tested in 
10 triple-negative cell lines, showed supra-additive effect in virtually 100% of the tested 
cases (Figure 19A A,B). The drug combinations that showed highest synergistic effect 
were tested also in animal models of breast cancer. As shown in Figure 22 tumor 
growth inhibition was significantly higher for any of the tested combinations compared to 
single agents that demonstrated models effect both in vitro (Figure 17 and 18) and in 
vivo Figure 22. Although future research should be conducted to confirming that the de-
regulated signalling pathways in tumours are similar to those in tumour cell lines,  we 
consider that our therapeutic results are valid, since we found that the GO pathways 
(Figure 7) and driver kinases (Figure 9) overlapped between the tumour cell lines and 
patient tumour samples. Altogether, our results suggest that many different 
combinations of elevated output in such disparate pathways as "translational control" 
(pP70S6K), "calcium signaling" (PRKCE), "cell replication" (CDK6), "growth factor 
signaling" (c-KIT), "DNA damage" (pPNKP) and "MAP-kinases" (pERK1/2) lead to an 
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 We have accumulated compelling evidence indicating that phosphoproteomic 
profiling of triple-negative breast cancer could provide both identification of subgroups 
with different clinical outcome and more importantly novel therapeutic solution for 
patients with adverse clinical prognosis. In summary we found that: 
1. High-through mass-spectrometry based phosphoproteomics is a powerful tool 
that allows gain of new knowledge by identification of phosphorylated proteins 
that are not previously linked to triple-negative breast cancer. 
2. Phosphorylated proteins identified in triple-negative breast cancer cases and cell 
lines are intrinsically different and cluster into two different clusters, however  
they could be reduced to a much smaller number of overlapping driver kinases. 
3. Kinase set enrichment analysis pinpointed significantly enriched kinases driving 
the profiles of aggressive triple-negative breast cancer cases. 
4. Translation of mass-spectrometry into immunohistochemistry, even thought    
technically demanding, is feasible and provides generation of prognostic and/or 
predictive signatures. 
5. We identified six kinases, PRKCE, P70S6K, PNKP, ERK, c-KIT and CDK6 which 
increased activity appears to drive aggressive clinical course of TNBC.  
6. Study of the status of each of six kinases in the tumors from the validation set 
allowed us the assembly of a basic kinome landscape of TNBC. One of the found 
patterns was characterized by the lack of high activity in the six kinases and was 
associated with a very high long-term relapse-free rate. Other pattern in which 
one or more kinases showed hyperactivation was associated with aggressive 
clinical course. 
7. Hyperactivity of one or more kinases confers greater than 9-fold risk of relapse, 
even when adjusted for the conventional risk factors. Moreover K-high is able to 
stratify the outcome of patients with TNBC better than any currently available 
prognostic tool.  
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8.  Our strategy allowed the design of potential two-by-two drug screening 
combinations with currently existing targeted drugs. The 15 doublets showed 
supra-additive effect in almost all triple-negative cell lines tested.  
9.  Targeting ERK, c-KIT, CDK6 and PNKP in MDA-MB-231 aggressive cell lines 
showed modest therapeutic potential. However drug combinations demonstrate 
significant reduction of tumor growth.  
10.   The identified drug combinations may serve as novel therapeutic solutions for 
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Hemos llegado a evidencias convincentes que nos indican que los perfiles de 
fosforilacion de cáncer de mama triple negativo podrían proporcionarnos una 
identificación de los distintos subgrupos en base a su  evolución clínica y más 
importante proponer una solución terapéutica para los pacientes con pronóstico clínico 
adverso. En resumen se encontró que:  
1. El estudio de la fosfoproteómica basado en técnicas de espectrometría de 
masas es una herramienta útil que nos permite, mediante la identificacion de 
nuevas proteínas fosforiladas que previamente no estaban vinculadas al cáncer 
de mama triple negarivo aumentar el conocimiento que tenemos de este tipo de 
cáncer  
2. Las proteínas fosforiladas identificadas en las muestras de pacientes de cáncer 
de mama triple negativo y las identificadas en las líneas celulares son diferentes 
y se agrupan en dos grupos diferentes, sin embargo estas podrían reducirse a 
un número mucho menor si solo tenemos en cuenta las que están presentes a la 
vez en ambos grupos.  
3. Mediante el estudio de enriquecimiento de fosfopéptidos se identificaron kinasas  
que estaban significativamente enriquecidas en los casos  de cáncer de cancer 
de mama con recaida y que podrían conducir a este fenotipo agresivo. 
4. Aplicar los datos obtenidos mediante espectometría de masas mediante técnicas 
inmunohistológicas es factible y proporciona la generación de nuevos 
marcadores de pronóstico y predictivos.  
5. Se han identificado seis kinasas: PRKCE, P70S6K, PNKP, ERK, c-KIT y CDK6 
cuya mayor actividad es capaz de dirigir el curso clínico agresivo del TNBC.  
6. El estudio del estatus de cada una de las seis kinasas identificadas usando el 
set de validación  nos permitió tener una visión general del quinoma básico 
presente en los casos de TNBC. Uno de los patrones encontrados se caracterizó 
por la falta de actividad alta en las seis kinasas y se asoció con una probabilidad 
muy alta de no recaida a largo plazo. Sin embargo, el otro patrón en el que una o 
más de las kinasas identificadas presentaban valores de hiperactivatición se 
asoció con un curso clínico agresivo.  
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7. La hiperactividad de una o varias de las kinasas identificadas confiere un mayor 
riesgo de recaída (9 veces mayor). Por otra parte alta-K es capaz de estratificar 
el comportamiento de los pacientes con TNBC mejor que cualquier herramienta 
de pronóstico actualmente disponible. 
8. Nuestra estrategia permitío el diseño de 2 por 2 combinaciones con farmacos 
existentes actualmente. Los 15 dobletes mostraron un efecto aditivo en casi 
todas las celulas líneares triple negativas probadas.  
9. El uso de fármacos dirigidos contra ERK, c-KIT, CDK6 y PNKP en las líneas 
celulares agresivas, MDA-MB-231, demostró un modesto potencial terapéutico. 
Sin embargo, el uso de las combinaciones de fármacos demostraron una 
reducción significativa del crecimiento tumoral. 
10. Las combinaciones de medicamentos identificadas pueden servir como nuevas 
soluciones terapéuticas para pacientes positivos de alta-K aunque es necesarió 
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